

1 Understanding the genetic complexity of puberty timing 2 across the allele frequency spectrum

3 Katherine A Kentistou^{1*}, Lena R Kaisinger^{1*}, Stasa Stankovic¹, Marc Vaudel^{2,3}, Edson
4 M de Oliveira⁴, Andrea Messina⁵, Robin G Walters^{6,7}, Xiaoxi Liu⁸, Alexander S Busch^{9,10},
5 Hannes Helgason^{11,12}, Deborah J Thompson¹³, Federico Santon⁵, Konstantin M
6 Petricek¹⁴, Yassine Zouaghi⁵, Isabel Huang-Doran⁴, Daniel F Gudbjartsson^{11,12}, Eirik
7 Bratland^{2,15}, Kuang Lin⁶, Eugene J Gardner¹, Yajie Zhao¹, Raina Jia¹, Chikashi
8 Terao^{8,16,17}, Margie Riggan¹⁸, Manjeet K Bolla¹³, Mojgan Yazdanpanah¹⁹, Nahid
9 Yazdanpanah¹⁹, Jonath P Bradfield^{20,21}, Linda Broer^{22,23}, Archie Campbell²⁴, Daniel I
10 Chasman²⁵, Diana L Cousminer^{26,27,28}, Nora Franceschini²⁹, Lude H Franke³⁰, Giorgia
11 Giroto^{31,32}, Chunyan He^{33,34}, Marjo-Riitta Järvelin^{35,36,37,38,39}, Peter K Joshi⁴⁰, Yoichiro
12 Kamatani⁴¹, Robert Karlsson⁴², Jian'an Luan¹, Kathryn L Lunetta^{43,44}, Reedik Mägi⁴⁵,
13 Massimo Mangino^{46,47}, Sarah E Medland^{48,49,50}, Christa Meisinger⁵¹, Raymond
14 Noordam⁵², Teresa Nutile⁵³, Maria Pina Concac³¹, Ozren Polašek^{54,55}, Eleonora
15 Porcu^{56,57}, Susan M Ring^{58,59}, Cinzia Sala⁶⁰, Albert V Smith^{61,62}, Toshiko Tanaka⁶³, Peter
16 J van der Most⁶⁴, Veronique Vitart⁶⁵, Carol A Wang^{66,67}, Gonneke Willemsen⁶⁸, Marek
17 Zygumt⁶⁹, Thomas U Ahearn⁷⁰, Irene L Andrulic^{71,72}, Hoda Anton-Culver⁷³, Antonis C
18 Antoniou¹³, Paul L Auer⁷⁴, Catriona LK Barnes⁴⁰, Matthias W Beckmann⁷⁵, Amy
19 Berrington⁷⁶, Natalia V Bogdanova^{77,78,79}, Stig E Bojesen^{80,81}, Hermann Brenner^{82,83,84},
20 Julie E Buring²⁵, Federico Canzian⁸⁵, Jenny Chang-Claude^{86,87}, Fergus J Couch⁸⁸,
21 Angela Cox⁸⁹, Laura Crisponi⁵⁶, Kamila Czene⁴², Mary B Daly⁹⁰, Ellen W Demerath⁹¹,
22 Joe Dennis¹³, Peter Devilee^{92,93}, Immaculata De Vivo^{94,95}, Thilo Dörk⁷⁸, Alison M
23 Dunning⁹⁶, Miriam Dwek⁹⁷, Johan G Eriksson⁹⁸, Peter A Fasching⁹⁹, Lindsay
24 Fernandez-Rhodes¹⁰⁰, Liana Ferrelli⁵⁶, Olivia Fletcher¹⁰¹, Manuela Gago-Dominguez¹⁰²,
25 Montserrat García-Closas⁷⁰, José A García-Sáenz¹⁰³, Anna González-Neira¹⁰⁴, Harald
26 Grallert^{105,106}, Pascal Guénel¹⁰⁷, Christopher A Haiman¹⁰⁸, Per Hall^{42,109}, Ute Hamann¹¹⁰,
27 Hakon Hakonarson^{21,26,111,112}, Roger J Hart¹¹³, Martha Hickey¹¹⁴, Maartje J Hooning¹¹⁵,
28 Reiner Hoppe^{116,117}, John L Hopper¹¹⁸, Jouke-Jan Hottenga⁶⁸, Frank B Hu^{119,95}, Hanna
29 Hübner⁹⁹, David J Hunter^{94,6}, ABCTB Investigators¹²⁰, Helena Jernström¹²¹, Esther M
30 John^{122,123}, David Karasik^{124,125}, Elza K Khusnutdinova^{126,127}, Vessela N Kristensen^{128,129},
31 James V Lacey^{130,131}, Diether Lambrechts^{132,133}, Lenore J Launer¹³⁴, Penelope A
32 Lind^{48,135,50}, Annika Lindblom^{136,137}, Patrik KE Magnusson⁴², Arto Mannermaa^{138,139}, Mark I
33 McCarthy^{140,141,142}, Thomas Meitinger¹⁴³, Cristina Menni⁴⁶, Kyriaki Michailidou^{13,144}, Iona Y
34 Millwood^{6,7}, Roger L Milne^{145,118}, Grant W Montgomery¹⁴⁶, Heli Nevanlinna¹⁴⁷, Ilja M
35 Nolte¹⁴⁸, Dale R Nyholt¹⁴⁹, Nadia Obi¹⁵⁰, Katie M O'Brien¹⁵¹, Kenneth Offit^{152,153}, Albertine
36 J Oldehinkel¹⁵⁴, Sisse R Ostrowski^{155,156}, Aarno Palotie^{157,158,159,160,161,162}, Ole B
37 Pedersen^{163,156}, Annette Peters^{106,164}, Giulia Pianigiani³¹, Dijana Plaseska-Karanfilska¹⁶⁵,
38 Anneli Pouta¹⁶⁶, Alfred Pozarickij⁶, Paolo Radice¹⁶⁷, Gad Rennert¹⁶⁸, Frits R
39 Rosendaal¹⁶⁹, Daniela Ruggiero^{53,170}, Emmanouil Saloustros¹⁷¹, Dale P Sandler¹⁵¹,
40 Sabine Schipf¹⁷², Carsten O Schmidt¹⁷², Marjanka K Schmidt^{173,174}, Kerrin Small⁴⁶,
41 Beatrice Spedicati³², Meir Stampfer^{94,95}, Jennifer Stone^{175,118}, Rulla M Tamimi^{176,94}, Lauren
42 R Teras¹⁷⁷, Emmi Tikkanen^{178,162}, Constance Turman^{94,179}, Celine M Vachon¹⁸⁰, Qin
43 Wang¹³, Robert Winqvist^{181,182}, Alicja Wolk¹⁸³, Babette S Zemel^{111,184}, Wei Zheng¹⁸⁵, Ko W
44 van Dijk^{93,186}, Behrooz Z Alizadeh¹⁴⁸, Stefania Bandinelli¹⁸⁷, Eric Boerwinkle¹⁸⁸, Dorret I
45 Boomsma^{68,189}, Marina Ciullo^{53,170}, Georgia Chenevix-Trench⁴⁸, Francesco Cucca^{56,57},
46 Tonu Esko⁴⁵, Christian Gieger^{105,106,190}, Struan FA Grant^{26,27,28,111,191}, Vilmundur

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

47 Gudnason^{61,62}, Caroline Hayward⁶⁵, Ivana Kolčić^{54,55}, Peter Kraft^{94,179}, Deborah A
48 Lawlor^{58,59}, Nicholas G Martin⁴⁸, Ellen A Nøhr¹⁹², Nancy L Pedersen⁴², Craig E
49 Pennell^{66,67,193}, Paul M Ridker²⁵, Antonietta Robino³¹, Harold Snieder¹⁴⁸, Ulla Sovio^{35,194},
50 Tim D Spector⁴⁶, Doris Stöckl¹⁹⁵, Cathie Sudlow^{24,196}, Nic J Timpson^{58,59}, Daniela
51 Toniolo⁶⁰, André Uitterlinden^{22,23}, Sheila Ulivi³¹, Henry Völzke¹⁷², Nicholas J Wareham¹,
52 Elisabeth Widen¹⁶², James F Wilson⁴⁰, The Lifelines Cohort Study[†], The Danish Blood
53 Donor study[†], The Ovarian Cancer Association Consortium[†], The Breast Cancer
54 Association Consortium[†], The Biobank Japan Project, The China Kadoorie Biobank
55 Collaborative Group[†], Paul DP Pharoah^{13,96}, Liming Li^{197,198}, Douglas F Easton^{13,96}, Pål
56 Njølstad^{2,199}, Patrick Sullem¹¹, Joanne M Murabito^{44,200}, Anna Murray²⁰¹, Despoina
57 Manousaki^{19,202,203}, Anders Juul^{204,205,206}, Christian Erikstrup^{207,208}, Kari Stefansson^{11,62},
58 Momoko Horikoshi²⁰⁹, Zhengming Chen^{6,7}, I Sadaf Farooqi⁴, Nelly Pitteloud^{5,210}, Stefan
59 Johansson^{2,15}, Felix R Day^{1*}, John RB Perry^{1,211*‡}, Ken K Ong^{1,212*}

60 1 MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Box
61 285 Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge CB2
62 0QQ, UK

63 2 Mohn Center for Diabetes Precision Medicine, Department of Clinical Science,
64 University of Bergen, NO-5020, Bergen, Norway

65 3 Department of Genetics and Bioinformatics, Health Data and Digitalization,
66 Norwegian Institute of Public Health, NO-0213, Oslo, Norway

67 4 University of Cambridge Metabolic Research Laboratories and NIHR Cambridge
68 Biomedical Research Centre, Wellcome-MRC Institute of Metabolic Science,
69 Addenbrooke's Hospital, Cambridge, UK

70 5 Division of Endocrinology, Diabetology, and Metabolism, Lausanne University
71 Hospital, 1011 Lausanne, Switzerland

72 6 Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF,
73 UK

74 7 MRC Population Health Research Unit, University of Oxford, Oxford OX3 7LF, UK

75 8 Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative
76 Medical Sciences, Yokohama, Japan

77 9 Department of General Pediatrics, University of Münster, Münster, Germany

78 10 Department of Growth and Reproduction, Copenhagen University Hospital -
79 Rigshospitalet, Copenhagen, Denmark

80 11 deCODE Genetics/Amgen, Inc., Reykjavik, Iceland

81 12 School of Engineering and Natural Sciences, University of Iceland, Reykjavik,
82 Iceland

83 13 Centre for Cancer Genetic Epidemiology, Department of Public Health and
84 Primary Care, University of Cambridge, Cambridge CB1 8RN, UK

85 14 Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin
86 and Humboldt-Universität zu Berlin, Institute of Pharmacology, Berlin, Germany

87 15 Department of Medical Genetics, Haukeland University Hospital, NO-5021,
88 Bergen, Norway

89 16 Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan

90 17 The Department of Applied Genetics, The School of Pharmaceutical Sciences,
91 University of Shizuoka, Shizuoka, Japan

92 18 Department of Gynecology, Duke University Medical Center, Durham, North

- 93 Carolina, USA
94 19 Research Center of the Sainte-Justine University Hospital, University of Montreal,
95 Montreal, Quebec, Canada
96 20 Quantinuum Research, Wayne, PA, USA
97 21 Center for Applied Genomics, Children’s Hospital of Philadelphia, Philadelphia,
98 PA, USA
99 22 Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
100 23 Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands
101 24 Centre for Genomic and Experimental Medicine, Institute of Genetics & Cancer,
102 University of Edinburgh, Edinburgh, UK
103 25 Division of Preventive Medicine, Brigham and Women's Hospital and Harvard
104 Medical School, Boston, MA 02215, USA
105 26 Division of Human Genetics, Children’s Hospital of Philadelphia, Philadelphia,
106 PA, USA
107 27 Department of Genetics, University of Pennsylvania, Philadelphia, PA, USA
108 28 Center for Spatial and Functional Genomics, Children’s Hospital of Philadelphia,
109 Philadelphia, PA, USA
110 29 Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA
111 30 Department of Genetics, University of Groningen, University Medical Center
112 Groningen, Groningen, The Netherlands
113 31 Institute for Maternal and Child Health – IRCCS “Burlo Garofolo”, Trieste, Italy
114 32 Department of Medicine, Surgery and Health Sciences, University of Trieste,
115 Trieste, Italy
116 33 Department of Epidemiology and Biostatistics, Department of Big Data in Health
117 Science, School of Public Health, Zhejiang University School of Medicine, Hangzhou
118 310058, China
119 34 Departments of Medical Oncology and Hematology, Sir Runrun Shaw Hospital,
120 School of Medicine, Zhejiang University, Hangzhou 310016, China
121 35 Department of Epidemiology and Biostatistics, MRC Health Protection Agency
122 (HPA) Centre for Environment and Health, School of Public Health, Imperial College
123 London, UK
124 36 Institute of Health Sciences, P.O.Box 5000, FI-90014 University of Oulu, Finland
125 37 Biocenter Oulu, P.O.Box 5000, Aapistie 5A, FI-90014 University of Oulu, Finland
126 38 Unit of Primary Care, Oulu University Hospital, Kajaanintie 50, P.O.Box 20, FI-
127 90220 Oulu, 90029 OYS, Finland
128 39 Department of Children and Young People and Families, National Institute for
129 Health and Welfare, Aapistie 1, Box 310, FI-90101 Oulu, Finland
130 40 Centre for Global Health Research, Usher Institute, University of Edinburgh,
131 Teviot Place, Edinburgh EH8 9AG, Scotland
132 41 Laboratory of Complex Trait Genomics, Department of Computational Biology
133 and Medical Sciences, Graduate School of Frontier Sciences, The University of
134 Tokyo, Tokyo, Japan
135 42 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
136 Stockholm, Sweden
137 43 Boston University School of Public Health, Department of Biostatistics. Boston,
138 Massachusetts 02118, USA

- 139 44 NHLBI's and Boston University's Framingham Heart Study, Framingham,
140 Massachusetts 01702-5827, USA
- 141 45 Institute of Genomics, University of Tartu, Tartu, Estonia
- 142 46 Department of Twin Research and Genetic Epidemiology, King's College London,
143 London, UK
- 144 47 NIHR Biomedical Research Centre at Guy's and St. Thomas' Foundation Trust,
145 London, UK
- 146 48 QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
- 147 49 School of Psychology, University of Queensland, Brisbane, Queensland, Australia
- 148 50 Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia
- 149 51 Epidemiology, Medical Faculty, University of Augsburg, University Hospital of
150 Augsburg, Augsburg, Germany
- 151 52 Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden
152 University Medical Center, Leiden, The Netherlands
- 153 53 Institute of Genetics and Biophysics "A. Buzzati-Traverso", CNR, Naples, Italy
- 154 54 University of Split School of Medicine, Split, Croatia
- 155 55 Algebra University College, Zagreb, Croatia
- 156 56 Institute of Genetics and Biomedical Research, National Research Council,
157 Cagliari, Sardinia 09042, Italy
- 158 57 University of Sassari, Department of Biomedical Sciences, Sassari, Sassari
159 07100, Italy
- 160 58 MRC Integrative Epidemiology Unit at the University of Bristol, UK
- 161 59 Population Health Science, Bristol Medical School, University of Bristol, UK
- 162 60 Division of Genetics and Cell Biology, San Raffele Hospital, Milano, Italy
- 163 61 Icelandic Heart Association, 201 Kopavogur, Iceland
- 164 62 Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland
- 165 63 National Institute on Aging, National Institutes of Health, Baltimore, Maryland,
166 USA
- 167 64 Department of Epidemiology, University of Groningen, University Medical Center
168 Groningen, The Netherlands
- 169 65 MRC Human Genetics Unit, Institute of Genetics and Cancer, University of
170 Edinburgh, Edinburgh EH4 2XU, UK
- 171 66 School of Medicine and Public Health, University of Newcastle, Newcastle, New
172 South Wales 2308, Australia
- 173 67 Hunter Medical Research Institute, Newcastle, New South Wales 2305, Australia
- 174 68 Dept of Biological Psychology, Vrije Universiteit, Amsterdam; Amsterdam Public
175 Health (APH) research institute, The Netherlands
- 176 69 Clinic of Gynaecology and Obstetrics, University Medicine Greifswald, Germany
- 177 70 Division of Cancer Epidemiology and Genetics National Cancer Institute, National
178 Institutes of Health, Department of Health and Human Services Bethesda, MD, USA
- 179 71 Fred A. Litwin Center for Cancer Genetics Lunenfeld-Tanenbaum Research
180 Institute of Mount Sinai Hospital Toronto, Ontario, Canada
- 181 72 Department of Molecular Genetics University of Toronto Toronto, Ontario,
182 Canada
- 183 73 Department of Medicine, Genetic Epidemiology Research Institute University of
184 California Irvine Irvine, CA, USA

- 185 74 Division of Biostatistics, Institute for Health and Equity, and Cancer Center
186 Medical College of Wisconsin Milwaukee, WI, USA
- 187 75 Department of Gynecology and Obstetrics, Comprehensive Cancer Center
188 Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg , University
189 Hospital Erlangen, Erlangen, Germany
- 190 76 Division of Genetics and Epidemiology The Institute of Cancer Research, London,
191 UK
- 192 77 Department of Radiation Oncology, Hannover Medical School, Hannover,
193 Germany
- 194 78 Gynaecology Research Unit, Hannover Medical School, Hannover, Germany
- 195 79 N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk,
196 Belarus
- 197 80 Copenhagen General Population Study, Herlev and Gentofte Hospital
198 Copenhagen University Hospital, Herlev, Denmark
- 199 81 Department of Clinical Biochemistry, Herlev and Gentofte Hospital Copenhagen
200 University Hospital, Herlev, Denmark
- 201 82 Division of Clinical Epidemiology and Aging Research German Cancer Research
202 Center (DKFZ), Heidelberg, Germany
- 203 83 Division of Preventive Oncology German Cancer Research Center (DKFZ) and
204 National Center for Tumor Diseases (NCT), Heidelberg, Germany
- 205 84 German Cancer Consortium (DKTK) German Cancer Research Center (DKFZ),
206 Heidelberg, Germany
- 207 85 Genomic Epidemiology Group German Cancer Research Center (DKFZ),
208 Heidelberg, Germany
- 209 86 Division of Cancer Epidemiology German Cancer Research Center (DKFZ),
210 Heidelberg, Germany
- 211 87 Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH)
212 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 213 88 Department of Laboratory Medicine and Pathology Mayo Clinic Rochester, MN,
214 USA
- 215 89 Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and
216 Metabolism, University of Sheffield, Sheffield, UK
- 217 90 Department of Clinical Genetics Fox Chase Cancer Center Philadelphia, PA, USA
- 218 91 Division of Epidemiology and Community Health, School of Public Health,
219 University of Minnesota, USA
- 220 92 Department of Pathology, Leiden University Medical Center, Leiden, The
221 Netherlands
- 222 93 Department of Human Genetics, Leiden University Medical Center, Leiden, The
223 Netherlands
- 224 94 Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston,
225 Massachusetts 02115, USA
- 226 95 Channing Division of Network Medicine, Department of Medicine, Brigham and
227 Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
- 228 96 Centre for Cancer Genetic Epidemiology, Department of Oncology, University of
229 Cambridge, Cambridge CB1 8RN, UK
- 230 97 School of Life Sciences, University of Westminster, London, UK

- 231 98 Department of General Practice and Primary Healthcare , University of Helsinki,
232 Helsinki University Hospital, Helsinki, Finland
- 233 99 Department of Gynecology and Obstetrics, Comprehensive Cancer Center
234 Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University
235 Hospital Erlangen, Erlangen, Germany
- 236 100 Department of Biobehavioral Health, Pennsylvania State University, University
237 Park, PA, USA
- 238 101 The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer
239 Research, London, UK
- 240 102 Genomic Medicine Group, International Cancer Genetics and Epidemiology
241 Group Fundación Pública Galega de Medicina Xenómica, Instituto de Investigación
242 Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de
243 Santiago, SERGAS Santiago de Compostela, Spain
- 244 103 Medical Oncology Department, Hospital Clínico San Carlos Instituto de
245 Investigación Sanitaria San Carlos (IdISSC), Centro Investigación Biomédica en Red
246 de Cáncer (CIBERONC), Madrid, Spain
- 247 104 Human Genotyping Unit-CeGen, Spanish National Cancer Research Centre
248 (CNIO), Madrid, Spain
- 249 105 Research Unit of Molecular Epidemiology, Helmholtz Zentrum München–
250 German Research Center for Environmental Health, Neuherberg, Germany
- 251 106 Institute of Epidemiology, Helmholtz Zentrum München–German Research
252 Center for Environmental Health, Neuherberg, Germany
- 253 107 Team "Exposome and Heredity", CESP, Gustave Roussy INSERM, University
254 Paris-Saclay, UVSQ Villejuif, France
- 255 108 Department of Preventive Medicine, Keck School of Medicine, University of
256 Southern California, Los Angeles, CA, USA
- 257 109 Department of Oncology, Södersjukhuset, Stockholm, Sweden
- 258 110 Molecular Genetics of Breast Cancer, German Cancer Research Center
259 (DKFZ), Heidelberg, Germany
- 260 111 Department of Pediatrics, University of Pennsylvania Perelman School of
261 Medicine, Philadelphia, PA, USA
- 262 112 Division of Pulmonary Medicine, Children's Hospital of Philadelphia,
263 Philadelphia, PA, USA
- 264 113 Division of Obstetrics and Gynaecology, University of Western Australia,
265 Western Australia, Australia
- 266 114 Department of Obstetrics and Gynaecology at the University of Melbourne and
267 The Royal Women's Hospital, Victoria, Australia
- 268 115 Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam,
269 The Netherlands
- 270 116 Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart,
271 Germany
- 272 117 University of Tübingen, Tübingen, Germany
- 273 118 Centre for Epidemiology and Biostatistics, Melbourne School of Population and
274 Global Health, The University of Melbourne Melbourne, Victoria, Australia
- 275 119 Department of Nutrition, Harvard T.H. Chan School of Public Health School of
276 Public Health, Boston, Massachusetts 02115, USA

277 120 Australian Breast Cancer Tissue Bank, Westmead Institute for Medical
278 Research, University of Sydney, Sydney, New South Wales, Australia
279 121 Oncology, Department of Clinical Sciences in Lund, Lund University, Lund,
280 Sweden
281 122 Department of Epidemiology and Population Health, Stanford University School
282 of Medicine Stanford, CA, USA
283 123 Department of Medicine, Division of Oncology Stanford Cancer Institute,
284 Stanford University School of Medicine Stanford, CA, USA
285 124 Hebrew SeniorLife Institute for Aging Research, Boston, Massachusetts, USA
286 125 Harvard Medical School, Boston, Massachusetts, USA
287 126 Institute of Biochemistry and Genetics of the Ufa Federal Research Centre of
288 the Russian Academy of Sciences, Ufa, Russia
289 127 Department of Genetics and Fundamental Medicine, Bashkir State University,
290 Ufa, Russia
291 128 Department of Medical Genetics, Oslo University Hospital and University of
292 Oslo, Oslo, Norway
293 129 Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo,
294 Norway
295 130 Department of Computational and Quantitative Medicine, City of Hope Duarte,
296 CA, USA
297 131 City of Hope Comprehensive Cancer Center, City of Hope Duarte, CA, USA
298 132 Laboratory for Translational Genetics, Department of Human Genetics, KU
299 Leuven, Leuven, Belgium
300 133 VIB Center for Cancer Biology, VIB, Leuven, Belgium
301 134 Laboratory of Epidemiology and Population Sciences, National Institute on
302 Aging, Intramural Research Program, National Institutes of Health, Bethesda,
303 Maryland, 20892, USA
304 135 School of Biomedical Sciences, Queensland University of Technology, Brisbane,
305 Queensland, Australia
306 136 Department of Molecular Medicine and Surgery, Karolinska Institutet,
307 Stockholm, Sweden
308 137 Department of Clinical Genetics, Karolinska University Hospital, Stockholm,
309 Sweden
310 138 Translational Cancer Research Area, University of Eastern Finland, Kuopio,
311 Finland
312 139 Institute of Clinical Medicine, Pathology and Forensic Medicine, University of
313 Eastern Finland, Kuopio, Finland
314 140 Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
315 141 Oxford Centre for Diabetes, Endocrinology, & Metabolism, University of Oxford,
316 Churchill Hospital, Oxford OX3 7LJ, UK
317 142 NIHR Oxford Biomedical Research Centre, Churchill Hospital, OX3 7LE Oxford,
318 UK
319 143 Institute of Human Genetics, Klinikum rechts der Isar, Technical University of
320 Munich, School of Medicine, Munich, Germany
321 144 Biostatistics Unit, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus
322 145 Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria,

323 Australia
324 146 Institute for Molecular Bioscience, The University of Queensland, Brisbane,
325 Queensland, Australia
326 147 Department of Obstetrics and Gynecology, Helsinki University Hospital,
327 University of Helsinki, Helsinki, Finland
328 148 Department of Epidemiology, University of Groningen, University Medical Center
329 Groningen, Groningen, The Netherlands
330 149 School of Biomedical Sciences, Faculty of Health, Centre for Genomics and
331 Personalised Health, Queensland University of Technology, Brisbane, Queensland,
332 Australia
333 150 Institute for Medical Biometry and Epidemiology, University Medical Center
334 Hamburg-Eppendorf, Hamburg, Germany
335 151 Epidemiology Branch National Institute of Environmental Health Sciences, NIH
336 Research Triangle Park, NC, USA
337 152 Clinical Genetics Research Lab, Department of Cancer Biology and Genetics
338 Memorial Sloan Kettering Cancer Center New York, NY, USA
339 153 Clinical Genetics Service, Department of Medicine Memorial Sloan Kettering
340 Cancer Center New York, NY, USA
341 154 Interdisciplinary Center Psychopathology and Emotion Regulation, University
342 Medical Center Groningen, University of Groningen, The Netherlands
343 155 Department of Clinical Immunology, Rigshospitalet - University of Copenhagen,
344 Copenhagen, Denmark
345 156 Department of Clinical Medicine, Faculty of health and medical sciences,
346 University of Copenhagen, Denmark
347 157 Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General
348 Hospital and Harvard Medical School, Boston, Massachusetts, USA
349 158 Medical and Population Genetics Program, Broad Institute of MIT and Harvard,
350 Cambridge, Massachusetts, USA
351 159 Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard,
352 Cambridge, Massachusetts, USA
353 160 Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
354 UK
355 161 Analytic and Translational Genetics Unit, Massachusetts General Hospital and
356 Harvard Medical School, Boston, Massachusetts, USA
357 162 Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki,
358 Finland
359 163 Department of Clinical Immunology, Zealand University Hospital, Køge,
360 Denmark
361 164 Institute for Medical Information Processing, Biometry and Epidemiology - IBE,
362 Ludwig-Maximilians-Universität München, Munich, Germany
363 165 Research Centre for Genetic Engineering and Biotechnology "Georgi D.
364 Efremov" MASA Skopje Republic of North Macedonia
365 166 National Institute for Health and Welfare, Finland
366 167 Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of
367 Research Fondazione IRCCS, Istituto Nazionale dei Tumori (INT), Milan, Italy
368 168 Clalit National Cancer Control Center, Carmel Medical Center and Technion,

369 Faculty of Medicine, Haifa, Israel
370 169 Department of Clinical Epidemiology, Leiden University Medical Center, Leiden,
371 The Netherlands
372 170 IRCCS Neuromed, Pozzilli, Isernia, Italy
373 171 Department of Oncology, University Hospital of Larissa, Larissa, Greece
374 172 Institute for Community Medicine, University Medicine Greifswald, Germany
375 173 Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam,
376 The Netherlands
377 174 Division of Psychosocial Research and Epidemiology, The Netherlands Cancer
378 Institute - Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands
379 175 Genetic Epidemiology Group, School of Population and Global Health,
380 University of Western Australia Perth, Western Australia, Australia
381 176 Department of Population Health Sciences Weill Cornell Medicine New York,
382 NY, USA
383 177 Department of Population Science American Cancer Society Atlanta, GA, USA
384 178 Public Health Genomics Unit, Department of Chronic Disease Prevention,
385 National Institute for Health and Welfare, Helsinki, Finland
386 179 Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan
387 School of Public Health, Boston, MA, 02115, USA
388 180 Department of Quantitative Health Sciences, Division of Epidemiology Mayo
389 Clinic Rochester, MN, USA
390 181 Laboratory of Cancer Genetics and Tumor Biology, Translational Medicine
391 Research Unit, Biocenter Oulu, University of Oulu, Oulu, Finland
392 182 Laboratory of Cancer Genetics and Tumor Biology, Northern Finland Laboratory
393 Centre Oulu, Oulu, Finland
394 183 Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
395 184 Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of
396 Philadelphia, Philadelphia, PA, USA
397 185 Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology
398 Center, Vanderbilt-Ingram Cancer Center Vanderbilt University School of Medicine
399 Nashville, TN, USA
400 186 Department of Internal Medicine, Division of Endocrinology, Leiden University
401 Medical Center, Leiden, The Netherlands
402 187 Geriatric Unit, Local Health Toscana Centro, Florence, Italy
403 188 Human Genetics Center, University of Texas Health Science Center at Houston,
404 Houston, TX, USA
405 189 Amsterdam Reproduction & Development research institute, Amsterdam, The
406 Netherlands
407 190 German Center for Diabetes Research (DZD), Neuherberg, Germany
408 191 Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia,
409 Philadelphia, PA, USA
410 192 Institute of Clinical Research, University of Southern Denmark, Department of
411 Obstetrics & Gynecology, Odense University Hospital, Denmark
412 193 Department of Maternity and Gynaecology, John Hunter Hospital, Newcastle,
413 New South Wales 2305, Australia
414 194 Department of Obstetrics and Gynaecology, University of Cambridge,

- 415 Cambridge, UK
416 195 Gesundheitsamt Fürstentfeldbruck, Regierung von Oberbayern,
417 Fürstentfeldbruck, Germany
418 196 Centre for Medical Informatics, Usher Institute, University of Edinburgh
419 197 Department of Epidemiology and Biostatistics, School of Public Health, Peking
420 University, Beijing, China
421 198 Center for Public Health and Epidemic Preparedness and Response, Peking
422 University, Beijing, China
423 199 Department of Pediatrics and Adolescents, Haukeland University Hospital, NO-
424 5021, Bergen, Norway
425 200 Boston University Chobanian & Avedisian School of Medicine, Department of
426 Medicine, Section of General Internal Medicine, Boston, MA 02118, USA
427 201 Genetics of Complex Traits, University of Exeter Medical School, University of
428 Exeter, RILD Level 3, Royal Devon & Exeter Hospital, Barrack Road, Exeter, EX2
429 5DW, UK
430 202 Department of Pediatrics, University of Montreal, Montreal, Canada
431 203 Department of Biochemistry and Molecular Medicine, University of Montreal,
432 Montreal, Canada
433 204 Department of Growth and Reproduction, Copenhagen University Hospital -
434 Rigshospitalet, Copenhagen, Denmark
435 205 International Center for Research and Research Training in Endocrine
436 Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen
437 University Hospital - Rigshospitalet, Copenhagen, Denmark
438 206 Department of Clinical Medicine, University of Copenhagen, Copenhagen,
439 Denmark
440 207 Department of Clinical Immunology, Aarhus University Hospital, Aarhus,
441 Denmark
442 208 Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
443 209 Laboratory for Genomics of Diabetes and Metabolism, RIKEN Center for
444 Integrative Medical Sciences, Yokohama, Japan
445 210 Faculty of Biology and Medicine, University of Lausanne, Lausanne 1005,
446 Switzerland
447 211 Metabolic Research Laboratory, Wellcome-MRC Institute of Metabolic Science,
448 University of Cambridge School of Clinical Medicine, Cambridge CB2 0QQ, UK
449 212 Department of Paediatrics, University of Cambridge, Cambridge CB2 0QQ, UK

450 * These authors contributed equally to this work.

451 † A full list is provided in the supplement.

452 ‡ Correspondence should be addressed to: john.perry@mrc-epid.cam.ac.uk

453

454 **Abstract**

455 Pubertal timing varies considerably and has been associated with a range of health
456 outcomes in later life. To elucidate the underlying biological mechanisms, we
457 performed multi-ancestry genetic analyses in ~800,000 women, identifying 1,080
458 independent signals associated with age at menarche. Collectively these loci
459 explained 11% of the trait variance in an independent sample, with women at the top
460 and bottom 1% of polygenic risk exhibiting a ~11 and ~14-fold higher risk of delayed
461 and precocious pubertal development, respectively. These common variant analyses
462 were supported by exome sequence analysis of ~220,000 women, identifying several
463 genes, including rare loss of function variants in *ZNF483* which abolished the impact
464 of polygenic risk. Next, we implicated 660 genes in pubertal development using a
465 combination of *in silico* variant-to-gene mapping approaches and integration with
466 dynamic gene expression data from mouse embryonic GnRH neurons. This included
467 an uncharacterized G-protein coupled receptor *GPR83*, which we demonstrate
468 amplifies signaling of *MC3R*, a key sensor of nutritional status. Finally, we identified
469 several genes, including ovary-expressed genes involved in DNA damage response
470 that co-localize with signals associated with menopause timing, leading us to
471 hypothesize that the ovarian reserve might signal centrally to trigger puberty.
472 Collectively these findings extend our understanding of the biological complexity of
473 puberty timing and highlight body size dependent and independent mechanisms that
474 potentially link reproductive timing to later life disease.

475 Introduction

476 Age at menarche (AAM), the onset of menses in females, represents the start of
477 reproductive maturity and is a widely reported marker of pubertal timing. Menarche
478 normally occurs between ages 10 to 15 years¹, and its variation is associated with risks
479 of several health outcomes, including obesity, type 2 diabetes (T2D), cardiovascular
480 disease, and hormone-sensitive cancers^{2,3,4,5,6}. Thus, widespread secular trends
481 towards earlier puberty timing may have an important impact on public health⁷. AAM
482 is a highly polygenic trait⁸ and previous genome-wide association studies (GWAS)
483 have identified ~400 common genetic loci^{9,10,11,12,13}, the vast majority of which were
484 discovered in samples of European ancestry. AAM has a strong genetic correlation
485 with male puberty timing ($R_g=0.68$)¹⁴, as well as with adiposity (BMI, $R_g=-0.35$)⁹ and
486 specific pathways have been identified that link nutrient sensing to reproductive
487 hormone axis activation. For example, we recently reported that *MC3R* is the key
488 hypothalamic sensor linking nutritional status to puberty timing¹⁵.

489 Previously reported GWAS signals in ~370,000 women of European ancestry
490 explained ~7.4% of the population variance in AAM, corresponding to ~25% of the
491 estimated heritability⁹. Here, through an expanded GWAS in up to 799,845 women,
492 including 166,890 of East Asian ancestry, we identify 1080 independent signals for
493 AAM. Female participants who carry an excess of these alleles have equivalent risk of
494 precocious or delayed puberty compared to those carrying clinically relevant
495 monogenic alleles. We complement these common variant analyses by undertaking
496 the first large-scale assessment of rare variation in puberty timing in 222,283 women
497 with exome sequence data. Through subsequent variant to gene mapping approaches,
498 we implicate 660 genes, which collectively shed further light on the biological
499 determinants of puberty timing and the mechanisms linking it to disease risks.

500 Results

501 We performed a GWAS meta-analysis for AAM, in up to 799,845 women, by
502 combining data from five strata: i) 38 ReproGen consortium cohorts (N=180,269), ii)
503 UK Biobank (N=238,040), iii) the Breast Cancer Association Consortium and the
504 Ovarian Cancer Association Consortium (N=137,815), iv) 23andMe, Inc. (N=76,831),
505 and v) three East Asian biobanks: the China Kadoorie Biobank, the Biobank Japan,
506 and the Korean Genome and Epidemiology Study (N=166,890). All studies provided
507 GWAS data imputed to at least 1000 Genomes reference panel density
508 (Supplementary Table 1), yielding a total of ~12.7 million genetic variants in the final
509 meta-analysis. We did not find evidence of test statistic inflation due to population
510 structure (LDSC intercept=1.07, SE=0.03).

511 To maximise the discovery of genomic signals for AAM, we used a combination of
512 distance-based clumping and approximate conditional analysis (see Methods) in the
513 European-strata meta-analysis and in the all-ancestry meta-analysis, to identify signals
514 that are homogenous across the two ancestry groups. European-strata identified
515 signals (N=935) were supplemented with additional signals from the all-ancestry
516 analysis (N=145), resulting in a total of 1080 statistically independent signals for AAM

517 at a genome-wide significance ($P < 5 \times 10^{-8}$, Figure 1, Supplementary Table 2). Effect
518 sizes ranged from 3.5 months/allele for rarer alleles (MAF=0.9%) to ~5 days/allele for
519 more common variants (Supplementary Figure 1). Across the 145 additional signals,
520 we observed a median 1.16-fold increase in χ^2 for their association with AAM in the all-
521 ancestry analysis compared to European-only, which is proportionate to the added
522 number of East-Asian samples (~21% of the total).

523 Independent replication data from the Danish Blood Donors study (N=35,467)
524 (Supplementary Table 3) was available for 969/1080 signals¹⁶. Of these, 862 showed
525 directionally concordant associations (89%, $P_{\text{Binomial}} = 2.9 \times 10^{-147}$). In this independent
526 sample, the variance explained in AAM doubled from 5.6% for 355 available previously
527 reported signals⁹ to 11% for the 969 signals with available data. We also sought
528 indirect confirmation of AAM signals by association with age at voice breaking (AVB)
529 in men from the UK Biobank study (N=191,235) and 23andMe (N=55,871)
530 (Supplementary Table 4)^{17,18,14}. Of the 1080 AAM signals, 909/1080 (84%,
531 $P_{\text{Binomial}} = 2.6 \times 10^{-122}$) showed directionally concordant associations with AVB in UK
532 Biobank (including 354 at $P < 0.05$). Similarly, 852/1067 (79%, $P_{\text{Binomial}} = 1.8 \times 10^{-90}$) AAM
533 signals available in 23andMe showed directionally concordant associations with AVB
534 (217 at $P < 0.05$).

535 **Exome sequence analyses identify novel rare variants of large effect**

536 Previous genetic studies for AAM have largely been restricted to assessing the role of
537 common, largely non-coding, genetic variation. We sought to address this, by
538 performing an exome-wide association study (ExWAS) in 222,283 European ancestry
539 women in UK Biobank. Gene burden tests were performed by collapsing rare variants
540 (MAF < 0.1%) in each gene according to two overlapping predicted functional
541 categories: i) high-confidence protein truncating variants (PTVs) and ii) PTVs plus
542 missense variants with CADD score¹⁹ ≥ 25 (termed ‘damaging variants’, DMG). Six
543 genes were associated with AAM at exome-wide significance ($P < 1.54 \times 10^{-6}$,
544 0.05/32,434 tests, Figure 2, Supplementary Figure 2, Supplementary Figure 3,
545 Supplementary Figure 4, Supplementary Table 5). This included two genes previously
546 reported in rare monogenic disorders of puberty: *TACR3* (beta=0.62 years, $P = 3.2 \times 10^{-$
547 ¹⁹, N=489 DMG carriers) previously implicated in normosmic idiopathic
548 hypogonadotropic hypogonadism (IHH)²⁰, and *MKRN3* (beta=-0.59 years, $P = 1.4 \times 10^{-$
549 ⁷, N=187 DMG carriers) previously implicated in familial central precocious puberty
550 (CPP)²¹. Furthermore, *MC3R* (beta=0.33 years, $P = 1.6 \times 10^{-9}$, N=796 DMG carriers)
551 was recently reported to link nutrient sensing to key hypothalamic neurons¹⁵.

552 Of the three novel genes, *KDM4C* (beta=-0.33 years, $P = 2.5 \times 10^{-7}$, N=582 DMG
553 carriers) encodes a lysine-specific histone demethylase likely involved in
554 epigenetically regulating hypothalamic-pituitary-gonadal (HPG) axis genes²². A
555 second gene in this small family (*KDM5B*) showed near exome-wide significant
556 association with AAM ($P = 2.6 \times 10^{-6}$). In addition, *PDE10A* (beta=0.58 years, $P = 1.2 \times 10^{-$
557 ⁷, N=196 DMG carriers) encodes phosphodiesterase 10A, which regulates the
558 intracellular concentration of cyclic nucleotides and hence signal transduction²³.

559 Finally, *ZNF483* (beta=1.31 years, $P=4.9\times 10^{-11}$, N=59 DMG carriers), encodes a zinc
560 finger protein transcription factor involved in neuronal differentiation²⁴ and self-renewal
561 of pluripotent stem cells²⁵.

562 We were able to confirm four of these seven genes (*KDM4C*, *MC3R*, *TACR3* and
563 *ZNF483*) using voice breaking data in 178,625 men with exome sequence data in UK
564 Biobank ($P<0.05$, Figure 2, Supplementary Table 5). Lack of association with AVB at
565 *MKRN3* is consistent with previous reports that rare *MKRN3* mutations have greater
566 clinical impact in girls than boys^{21,26}. None of the seven genes showed an association
567 with childhood or adult adiposity (Supplementary Table 6).

568 In addition, we specifically examined rare variant associations with AAM or VB for
569 *ANOS1*, *CHD7*, *FGF8* and *WDR11*, which are clinically tested in hypogonadotropic
570 hypogonadism ('high evidence genes' on the Genomics England IHH panel²⁷) and
571 show a dominant or X-linked mode of inheritance (Supplementary Table 7). Normal
572 puberty timing (AAM: 10-15 years¹ or VB: "about average") was reported by all carriers
573 of PTVs in *ANOS1* (N=5 male) and *CHD7* (N=5 female, N=1 male). PTVs in *WDR11*
574 showed no association with delayed puberty with only 7/81 female and 5/68 male
575 carriers reporting delayed puberty. Female carriers of PTVs in *FGF8* showed some
576 evidence of later puberty (beta=1.4 years, $P=3.6\times 10^{-3}$, N=5/10 reported delayed
577 puberty) but with no effect in males (N=1/8 reported delayed puberty) (Supplementary
578 Figure 5). These observations highlight the lower penetrance of rare deleterious
579 variants in large population-based studies compared to in patient cohorts^{28, 29,30}.

580 **Common genetic variants influence risk of phenotypic extremes**

581 Rare pathogenic variants such as the above are described to cause disorders of
582 puberty. However, it remains unclear whether common genetic variants also contribute
583 to abnormal puberty timing. To assess this, we generated a polygenic score (PGS) of
584 AAM in a penalised regression framework using lassosum³¹ and data from our meta-
585 analysis of European ancestry cohorts but excluding UK Biobank. This PGS explained
586 ~12% of the phenotypic variance in UK Biobank. The PGS was informative in
587 individuals experiencing menarche as early as 8 years old and later than 20, well
588 beyond the normal AAM range (10 to 15 years, Supplementary Figure 6,
589 Supplementary Tables 8 and 9).

590 We next sought to understand how the risks of early (<10 years) and delayed (>15
591 years) AAM were influenced by the PGS. Women in the lowest 1% PGS centile
592 reported AAM at mean (SE) 11.49 (0.03) years, compared to 14.46 (0.04) years in the
593 top 1% PGS centile (Supplementary Figure 6, Supplementary Table 10). Compared
594 to women in the 50th PGS centile, those in the top 1% PGS were 10.7 times more likely
595 to report late AAM (OR [8.20-13.96], $P=2.6\times 10^{-68}$), while women in the lowest 1% PGS
596 were 14.2 times more likely to report early AAM (OR [7.13-28.39], $P=5.1\times 10^{-14}$).
597 Collectively these findings suggest that common genetic variants contribute to the risk
598 of rare clinical disorders of extremely early (precocious) and delayed puberty.

599 To evaluate the predictive performance of our AAM signals, we compared these to
600 phenotypic predictors in 3,140 female children from the ALSPAC study. The AAM
601 signals in combination explained more variance in AAM than childhood BMI, parental
602 BMI or mother's AAM (Supplementary Table 11). Furthermore, they had a similar
603 ability to predict extremes of AAM (beyond 2 SD) than a multi-phenotype predictor
604 (Supplementary Figure 7), and a combined genotype and phenotype model showed
605 high predictive ability for early AAM (AUROC = 0.75 [95% CI 0.68-0.82]) and late AAM
606 (AUROC = 0.85 [95% CI 0.81-0.92]).

607 We next tested whether carrying rare variants in the AAM ExWAS genes modifies the
608 common polygenic influence on AAM. We saw that the effect of the common variant
609 PGS on AAM was attenuated in the 49 unrelated carriers of DMG variants in *ZNF483*
610 ($\beta_{\text{non-carriers}}=0.564$ years/SD, SE=0.003; $\beta_{\text{carriers}}=0.084$, SE=0.214;
611 $P_{\text{interaction}}=0.025$, Figure 3, Supplementary Table 12). To confirm that this was not a
612 reflection of reduced power due to the low number of carriers, we estimated the
613 expected relationship for non-carriers in 10,000 random subsamples of 49 participants
614 and found that the observed carrier effect was unlikely by chance ($P=0.015$,
615 Supplementary Figure 8).

616 Using ENCODE ChIP-seq data³², we found that the transcriptional targets of *ZNF483*
617 are enriched for in the AAM GWAS (fGWAS³²; $P=2.6\times 10^{-7}$), and that greater *ZNF483*
618 binding confers earlier AAM (SLDP³³; $Z=-4.9$, $P=4.8\times 10^{-7}$), which is directionally-
619 concordant with our observed effect of rare DMG variants on later AAM. This was
620 further corroborated by functional-domain-specific gene burden analyses, which
621 showed a larger effect on AAM of *ZNF483* DMG variants located within zinc finger
622 domains ($\beta=1.615$ years, SE=0.293, $P=3.59\times 10^{-8}$), rather than DMG variants
623 outwith these domains ($\beta=0.816$ years, SE=0.298, $P=6.2\times 10^{-3}$, Figure 3). This data
624 suggests that rare DMG variants in *ZNF483* confer later AAM by disrupting the
625 protein's ability to bind to its multiple DNA targets.

626 **Implicating AAM genes through variant to gene mapping approaches**

627 To implicate putatively causal genes that underlie our 1080 common variant signals for
628 AAM, we developed the framework 'GWAS to Genes' (G2G) that integrates genomic
629 and functional data across six sources (Methods, Figure 1, Supplementary Tables 13-
630 16). We identified proximal genes (within 500kb up or downstream) to the 1080 AAM
631 signals and scored genes based on the degree of evidence linking our lead index
632 variants to the function of these genes. To achieve this, we implicated genes by
633 identifying signals that co-localised with a) known enhancers and regulatory
634 elements³⁴, b) non-synonymous variants, c) expression quantitative trait loci (eQTL)
635 specifically in tissues enriched for AAM associations (Supplementary Figure 9,
636 Supplementary Table 17), and d) circulating protein QTL (pQTL) from whole blood (see
637 Methods). In addition, we integrated gene-level associations for aggregated non-
638 synonymous common variants using MAGMA³⁵ and gene scores from PoPs³⁶, which
639 uses bulk human and mouse data with information on scRNA, gene pathways and

640 protein interactions to link genes to GWAS signals. Individual genes were further
641 upweighted if they were the nearest gene to the signal^{37,38}.

642 Using this approach, our 1080 signals were found to be proximal to 10,341 genes, of
643 which 660 ‘high-confidence AAM genes’ were identified as the highest-scoring gene at
644 a locus and with at least two lines of evidence (Supplementary Figure 10 &
645 Supplementary Table 18; top-scoring genes at each of the 1080 loci are also listed in
646 Supplementary Table 19). High-confidence AAM genes include established
647 components of the HPG axis that are disrupted in rare monogenic disorders of puberty
648 (*CADM1*, *CHD4*, *CHD7*, *FEZF1*, *GNRH1*, *KISS1*, *SPRY4*, *TAC3*, *TACR3*, *TYRO3*)³⁹,
649 and other recently reported candidate genes (*PLEKHA5*, *TBX3*, *ZNF462*)^{40,41}. Other
650 AAM genes have recognised roles in sex hormone secretion and gametogenesis
651 (*ACVR2A*, *CYP19A1*, *HSD17B7*, *INHBA*, *INHBB*, *MC3R*, *PCSK2*)⁴², are disrupted in
652 rare monogenic disorders of multiple pituitary hormone deficiency (*OTX2*, *SOX2*,
653 *SOX3*, *SST*)⁴³, monogenic obesity (*BDNF*, *LEPR*, *MC4R*, *NTRK2*, *PCSK1*, *SH2B1*)⁴⁴
654 or syndromes characterised by hypogonadism (Noonan Syndrome: *BRAF*, *SOS1*;
655 Bardet-Biedl Syndrome: *BBS4*; Prader-Willi/Angelman Syndrome: *NDN*, *SNRPN*,
656 *UBE3A*)^{45,46,47,48}. Other mechanisms implicated by high-confidence AAM genes
657 include: insulin and insulin-like growth factor (IGF) signalling (*CALCR*, *GHR*, *IGF1R*,
658 *INSR*, *NEUROD1*, *NSMCE2*, *PAPPA2*, *SOCS2*)⁴⁹; thyroid hormone signalling
659 (*THRB*)⁵⁰; and the Polycomb silencing complex (*CBX4*, *CTBP2*, *FBRSL1*, *JARID2*,
660 *PHC2*, *SCMH1*, *TNRC6A*)⁵¹. We also found strong supportive evidence for all genes
661 identified by the exome variant associations, except *KDM5B* (Supplementary Figure
662 11).

663 **Weight gain related and unrelated puberty signals**

664 Phenotypic, genetic and mechanistic links between higher BMI and earlier AAM are
665 well described¹⁵, but it is challenging to distinguish whether individual AAM signals
666 have a primary effect on puberty or weight status⁹. Here, 83 out of the 1080 AAM
667 signals colocalised (at $PP \geq 0.5$) and also showed genome-wide significant
668 association with adult BMI (Supplementary Table 20), and 53 further AAM signals
669 colocalised with adult BMI and showed association with BMI at $P < 4.6 \times 10^{-5}$ (based on
670 1080 tests). Of these 136 colocalising signals, at 126 the AAM-reducing allele was
671 associated with higher adult BMI (Supplementary Table 20).

672 To identify AAM signals with or without a primary effect on early weight gain, we
673 clustered the 1080 AAM signals by their associations with body weight from birth to
674 age 8 years (before the normal age at puberty onset) in the Norwegian MoBa Cohort
675 (N=26,681 children)⁵². We identified three trajectories: 464 AAM signals (44%) formed
676 a ‘moderate early weight gain’ trajectory, and 15 (1%) formed a ‘high early weight gain’
677 trajectory; both trajectories were characterised by effects of AAM-reducing alleles on
678 higher weight gain across early childhood. The remaining 586 (55%) AAM signals
679 formed a ‘no early weight gain’ trajectory; yet in combination AAM-reducing alleles in
680 this trajectory increased adult BMI (beta=0.487 kg/m²/year; $P=1.6 \times 10^{-20}$)
681 (Supplementary Tables 21 and 22, Figure 4, Supplementary Figure 12). This data
682 indicates a bidirectional causal relationship between AAM and body size, with greater

683 early weight gain leading to earlier AAM, and also earlier AAM leading to higher adult
684 BMI. This approach provides a clear distinction between AAM signals that have
685 primary effects on puberty timing or early weight gain.

686 **Pathway, tissue and cell-type enrichment of menarche-implicated genes**

687 Genome-wide common variant AAM associations were enriched for genes expressed
688 in several brain regions, and enrichment was highest in the hypothalamus. Outside the
689 brain, we also observed enrichment for genes expressed in the adrenal gland
690 (Supplementary Figure 9 & Supplementary Table 17).

691 We next performed gene-based pathway analyses on the 660 high-confidence AAM
692 genes using g:Profiler⁵³ and identified 83 enriched biological pathways
693 (Supplementary Table 23), which grouped into 24 clusters (Figure 4, Supplementary
694 Figure 13, Supplementary Table 24). These included a number of neuro-endocrine,
695 sexual development, protein and chromatin regulation pathways. To explore distinct
696 biological pathways by early weight trajectories, we repeated the gene-based
697 pathways analysis after stratifying the 660 high-confidence AAM genes into 'early
698 weight gain' AAM genes (N=341) or 'no early weight gain' AAM genes (N=315)
699 (Supplementary Table 25). Early weight gain AAM genes specifically highlighted
700 hormone regulation, feeding behaviour, rhythmical process, AKT phosphorylation
701 targets and peptidyl-serine modification (Supplementary Figure 14, Supplementary
702 Table 26). Conversely, the no early weight gain AAM genes highlighted female sex
703 differentiation, histone modification, negative regulation of transcription by RNA
704 polymerase II, synapse organisation and DNA repair (Supplementary Figure 15,
705 Supplementary Table 26). Head development and cellular response to stress
706 pathways were enriched among both early weight AAM gene groups (Figure 4,
707 Supplementary Figures 13-15, Supplementary Table 26).

708 To understand how AAM-associated genes may exert effects on the HPG axis, we
709 explored their expressional dynamics in mouse embryonic GnRH neurons [manuscript
710 in preparation]. RNAseq in GnRH neurons previously identified 2182 genes that
711 showed differential expression between embryonic migration stages (early,
712 intermediate or late, Figure 5), and were categorised into 23 spatio-temporal
713 expression trajectories [manuscript in preparation]. At the genome-wide level, we
714 observed enrichment for GWAS AAM associations among genes that become
715 upregulated in the late (Trajectory01, $P_{adj.}=3.8\times 10^{-5}$) and mid- to late-stages of GnRH
716 neuron development (Trajectory03, $P_{adj.}=0.032$, Supplementary Table 27), i.e. when
717 GnRH neurons have completed their migration process and start to make synaptic
718 connections. Of the 660 high-confidence AAM genes, 28 assign to Trajectory01
719 ($P_{Exact}=2.3\times 10^{-6}$), including *NEGR1* and *TNRC6A*, and 31 assign to Trajectory03
720 ($P_{Exact}=5.2\times 10^{-3}$), including *KDM4C*, *PDE10A* and *TP53BP1*. Both of these GnRH
721 expressional trajectories remained enriched when considering only the subset of non-
722 early weight high-confidence AAM genes (Trajectory01 $P_{Exact}=5.4\times 10^{-4}$; Trajectory03
723 $P_{Exact}=1.4\times 10^{-2}$), while Trajectory01 was also enriched when considering only AAM

724 genes that influence early weight gain (Trajectory01 $P_{\text{Exact}}=9.3\times 10^{-4}$; Trajectory03
725 $P_{\text{Exact}}=0.08$).

726 **GPCRs and puberty timing**

727 G protein-coupled receptors (GPCRs) regulate several endocrine processes and
728 diseases, including puberty timing⁵⁴ and are therapeutic targets. Here, 24 of the 161
729 brain-expressed GPCRs (Methods) were implicated in AAM by at least one G2G
730 predictor (Figure 6, Supplementary Table 28). These include *MC3R*, where we
731 recently reported that rare LOF variants, which impair signalling, were associated with
732 delayed puberty¹⁵, and *GPR83* which encodes a $G_{\alpha_{q11}}$ - and G_{α_i} -coupled GPCR widely
733 expressed in several brain regions^{55,56} and is implicated in energy metabolism⁵⁷. In
734 mice, *Gpr83* and *Mc3r* are reportedly co-expressed in key hypothalamic neurons that
735 control reproduction (KNDy neurons) and growth (GHRH neurons)¹⁵.

736 Since dimerisation between GPCRs may affect their signalling⁵⁸, we tested for physical
737 and functional interactions between *MC3R* and *GPR83* *in vitro*. Using a
738 Bioluminescence Resonance Energy Transfer (BRET)-based assay in HEK293 cells,
739 we observed a physical and specific interaction between *GPR83* and *MC3R*
740 (Supplementary Figure 16, Supplementary Table 29). We then tested whether *GPR83*
741 modifies canonical *MC3R* signalling, by measuring NDP- α -melanocyte-stimulating
742 hormone (NDP- α MSH)-stimulated cyclic AMP production in HEK293 cells following
743 transfection with plasmids encoding wild-type *GPR83* and *MC3R* separately or
744 together (1:1 ratio). *GPR83* and *MC3R* co-transfection increased cAMP production by
745 43% compared to *MC3R* alone ($P=0.03$, Figure 6, Supplementary Figure 16,
746 Supplementary Tables 30 and 31).

747 Consistent with this *in vitro* interaction, we observed statistical genetic epistasis
748 between the common AAM signals at *MC3R* rs3746619; a 5'UTR SNP highly
749 correlated with predicted deleterious coding variants, and *GPR83* rs592068; which
750 colocalises with eQTLs for *GPR83* in brain⁵⁹ and across tissues⁶⁰. Among white
751 European unrelated UK Biobank female participants, *MC3R* function-increasing
752 alleles conferred increasingly earlier AAM in the presence of *GPR83* expression-
753 increasing alleles ($\beta_{\text{interaction}}=-0.034 \pm 0.015$ years, $P_{\text{interaction}}=0.02$, Figure 6). These
754 findings extend our previous observation that *MC3R* loss of function causes delayed
755 puberty¹⁵, by indicating that increased *MC3R* function through enhanced *GPR83*
756 expression leads to earlier puberty timing.

757 **Joint regulation of ages at menarche and menopause**

758 Previous GWASs have estimated a modest shared genetic aetiology between AAM
759 and age at natural menopause (ANM) (genome-wide genetic correlation: $r_g=0.14$;
760 $P=0.003$)⁶¹. ANM gene candidates are mainly expressed in the ovary and implicate
761 DNA damage sensing and repair (DDR) processes that maintain genome stability and
762 hence preserve the ovarian primordial follicle pool⁶².

763 Of the 1080 AAM signals, nine colocalised (at $PP \geq 0.5$) and showed genome-wide
764 significant ($P < 5 \times 10^{-8}$) association with ANM, and a further 11 AAM signals colocalised

765 and showed association with ANM at $P < 4.6 \times 10^{-5}$ ($=0.05/1080$, Supplementary Table
766 32). We also considered if ANM signals influence AAM. Of the 290 previously reported
767 ANM signals⁶², 21 colocalised and showed association with AAM at $P < 1.7 \times 10^{-4}$
768 ($=0.05/290$), 13 of which were additional to the above AAM signals (Supplementary
769 Table 33). Consistent with the phenotypic association between AAM and ANM⁶³, most
770 of the shared common signals (25/33) showed directionally-concordant effects on AAM
771 and ANM (shifting reproductive lifespan earlier or later). Several of these shared
772 signals map to components of the HPG axis, including *GNRH1*, *INHBB* and *FSHB*
773 (lead SNP rs11031006), which has previously reported associations with related
774 reproductive phenotypes^{8,64,65}.

775 Several other shared AAM and ANM signals map to genes that encode components
776 of DDR processes (*CHD4*, *CHEK2*, *DEPTOR*, *E2F1*, *MSH6*, *MSI2*, *PPARG*, *RAD18*,
777 *RAD51*, *RAD52*, *SCAI*, *SPRY4*, *SUMO1*, *TP53BP1*, *TRIP12*, and *WWOX*, see
778 Supplementary Table 34), central to the establishment and maintenance of ovarian
779 oocyte numbers⁶², and not previously implicated in puberty timing. A notable example
780 is rs746979919 ($P_{\text{AAM}} = 1.5 \times 10^{-20}$; $P_{\text{ANM}} = 1.5 \times 10^{-34}$), which is intronic in *MSH6*, a DNA
781 mismatch repair gene that is primarily expressed in peripheral reproductive tissues,
782 such as ovary and uterus (Supplementary Table 35). Furthermore, the co-localised
783 ANM signal at *CHEK2* captures the previously described frameshift variant
784 1100delC⁶⁶. This association was further supported by the exome data, with the 347
785 women carrying rare *CHEK2* protein truncating variants (excluding 1100delC)
786 reporting on average 2 months later AAM ($SE = 0.99$, $P = 0.04$). *CHEK2* encodes a cell
787 cycle checkpoint inhibitor that plays a crucial role in culling oocytes with unrepaired
788 DNA damage⁶².

789 Three of the shared AAM and ANM signals that map to DDR genes were assigned to
790 the 'moderate early weight gain' trajectory and further colocalised with adult BMI
791 (*RAD52*: $P_{\text{BMI}} = 4.8 \times 10^{-22}$, *TP53BP1*: $P_{\text{BMI}} = 1.2 \times 10^{-5}$ and *TRIP12*: $P_{\text{BMI}} = 2.9 \times 10^{-13}$),
792 suggesting that some DDR genes might influence AAM via early weight gain
793 (Supplementary Table 20). Other shared AAM and ANM signals that map to DDR
794 genes were assigned to the 'no early weight gain' trajectory (*CHD4*, *MSH6*, *SCAI* and
795 *SUMO1*) and/or showed no association ($P > 0.05$) with adult BMI (*CHEK2*, *MSI2*,
796 *PPARG*, and *WWOX*).

797 **Summary and conclusions**

798 The GWAS signals identified by this expanded multi-ancestry GWAS double the
799 variance explained in AAM compared to previous findings⁹. Furthermore, the common
800 variant PGS contributes substantially to risks of extremely early and late puberty
801 timing. Future studies should explore the potential of this PGS to predict extreme
802 disorders of puberty timing, in contrast to the effects of known monogenic causes.

803 We describe the first systematic characterisation of common genetic determinants of
804 both ends of reproductive lifespan, AAM and ANM. The 33 identified shared signals
805 highlight the concordant effects of HPG axis genes on both AAM and ANM, and also
806 the influence of ovary-expressed genes involved in DNA damage response. DDR
807 processes have been well described to regulate ovarian oocyte numbers throughout
808 life⁶², but have not previously been implicated in puberty timing. When stratified by
809 their effects on early childhood weight, DDR pathways were enriched among AAM
810 genes that do not show a primary effect on early weight gain. Our findings suggest
811 that the ovarian reserve, established during early fetal development, might signal
812 centrally to influence the timing of puberty.

813 We address the considerable challenge of deriving biological insights from common
814 variant signals⁶⁷ by developing G2G (GWAS to Genes), an analytical pipeline that
815 integrates a variety of data sources to enable gene prioritisation. While comprehensive
816 experimental validation of G2G is infeasible, its utility is supported by the prioritisation
817 from GWAS AAM data of many genes with known involvement in sex hormone
818 regulation and rare monogenic or syndromic disorders of puberty, obesity and
819 hormone function. The validity of G2G prioritised genes is also supported by evidence
820 for their enrichment for dynamic expression in GnRH neurons during their late stage
821 of embryonic migration, when they begin their integration into the hypothalamic neural
822 network controlling puberty⁶⁸. Furthermore, we provide experimental support for one
823 novel high-scoring AAM gene, *GPR83*, which is co-expressed with, interacts with, and
824 enhances *MC3R* function. Future studies should explore further the emerging role of
825 brain expressed GPCRs in linking central nutritional sensing to reproductive function.

826 Finally, we provide one of the few examples to date of epistatic interaction between
827 common and rare genetic variants. Linked to puberty timing by both common and rare
828 variants, the transcription factor *ZNF483* has diverse binding sites across the genome.
829 We infer that greater *ZNF483* binding promotes earlier AAM, whereas rare deleterious
830 variants in *ZNF483* appear to abolish the influence of common genetic influence on
831 puberty timing.

832 Together, these insights shed light on mechanisms, including early weight gain and
833 adiposity, hormone secretion and response, and cellular susceptibility to DNA
834 damage, that potentially explain the widely reported relationships between earlier
835 puberty timing and higher risks of later life mortality, metabolic disease, and cancer.

836

837 **Acknowledgements**


838 This research has been conducted using the UK Biobank Resource under Application
839 Number 9905. Other study specific acknowledgements can be found in the
840 supplementary note.

841 **Data availability**

842 Cohorts should be contacted individually for access to their raw data. UK Biobank data
843 are available on application ([https://www.ukbiobank.ac.uk/enable-your-](https://www.ukbiobank.ac.uk/enable-your-research/register)
844 [research/register](https://www.ukbiobank.ac.uk/enable-your-research/register)). Summary statistics from the meta-analysis excluding 23andMe will
845 be made available upon publication. Access to the full summary statistics including
846 23andMe results, can be obtained from 23andMe after completion of a Data Transfer
847 Agreement (<https://research.23andme.com/dataset-access/>).


848 **Competing interests**

849 J.R.B.P. and E.J.G. are employed by Adrestia Therapeutics. D.J.T. is employed by
850 Genomics PLC. D.L.C. and J.P.B. are employed by GSK. E.T. is employed by Pfizer.
851 D.A.L. has received support from Roche Diagnostics and Medtronic Ltd for work
852 unrelated to the research in this paper. T.D.S. is co-founder and stakeholder of Zoe
853 Global Ltd. P.A.F. conducts research funded by Amgen, Novartis and Pfizer, he
854 received Honoraria from Roche, Novartis and Pfizer. M.W.B. conducts research
855 funded by Amgen, Novartis and Pfizer.




856

857 **Figure 1 | Age at menarche GWAS and gene prioritisation.** (a) Miami plot showing signals from the European meta-analysis for
 858 age at menarche (upper panel) and genome-wide G2G scores with names of the top 50 genes annotated (lower panel). The upper
 859 panel Y-axis is capped at $-\log_{10}(1 \times 10^{-150})$ for visibility. (b) The 50 top scoring genes implicated by G2G, annotated by their sources
 860 of evidence. Relevant data are included in Supplementary Tables 2 and 13-16.




861

862 **Figure 2 | Exome-wide rare (MAF <0.1%) variant associations with age at**
 863 **menarche.** (a) Manhattan plot showing gene burden test results for age at menarche.
 864 Genes passing exome-wide significance ($P < 1.54 \times 10^{-6}$) are highlighted; in addition,
 865 *KDM5B* shows a sub-threshold association ($P = 2.6 \times 10^{-6}$). Point shapes indicate variant
 866 predicted functional class (DMG, damaging; HC PTV, high confidence protein
 867 truncating). (b) QQ plot for gene burden tests. (c) Comparison of gene burden
 868 associations for age at menarche (female participants, years) and age at voice
 869 breaking (men, 3 categories). Relevant data are included in Supplementary Table 5.




870

871 **Figure 3 | Epistatic interactions between rare coding variants and common**
 872 **genetic susceptibility on age at menarche in UK Biobank.** (a) Interaction effects
 873 (95% CI) on age at menarche between a GWAS polygenic score (PGS) and carriage
 874 of qualifying rare variants in seven exome-highlighted genes. Predicted mean (95%
 875 CI) age at menarche in (b) non-carriers (black) and carriers (light blue) of rare variants
 876 in six genes without significant interaction effects and (c) in non-carriers (left panel)
 877 and carriers (right) of rare variants in *ZNF483* which shows significant interaction. In
 878 (c) points show individual age at menarche values. (d) Plot of individual rare damaging
 879 (DMG) variant associations with age at menarche by *ZNF483* functional domains. The
 880 coding part of *ZNF483* is depicted by the horizontal black line. Included damaging
 881 variants had a minor allele frequency (MAF) <0.1% and were annotated to either be
 882 high-confidence protein truncating variants or missense variants with CADD score
 883 ≥ 25 . Relevant data are included in Supplementary Table 12.




884

885 **Figure 4 | Stratification of age at menarche signals and biological pathway**
 886 **enrichments by their influence on early childhood weight.** (a) Proportion of GWAS
 887 signals for age at menarche by early childhood weight trajectory. (b) Biological
 888 pathways enriched for high confidence age at menarche genes, plus enrichment within
 889 early childhood weight trajectories. Row names describe pathway clusters. Strength
 890 of associations with individual pathways are indicated by circles. Circle size reflects
 891 the proportion of pathway genes that are high confidence age at menarche genes.
 892 The right-hand panel indicates whether each pathway cluster remains enriched for
 893 age at menarche genes when stratified by early childhood weight trajectory. Extended
 894 data are included in Supplementary Tables 21 and 23-26.



895
896
897
898
899
900
901
902

Figure 5 | Enrichment of gene drivers of GnRH migration and maturation in the age at menarche GWAS. (a) Schematic representation of the stages of GnRH neuron migration during embryonic development. Using RNAseq data, Pitteloud and colleagues [manuscript in preparation] grouped differentially-expressed genes into 23 expressional trajectories based on their comparative level of expression during the Early (yellow), Intermediate (amber) and Late (red) stages of GnRH migration. (b) Genome-wide MAGMA enrichment for age at menarche associations within each expression trajectory. (c) Trajectories significantly enriched at the genome-wide level in (b) show significant overlap with the 660 high-confidence age at menarche genes. Extended data are included in Supplementary Tables 18 and 27.



903

904 **Figure 6 | Interactions between G protein-coupled receptors (GPCRs) on age at menarche.** (a) 24 brain-expressed GPCRs
 905 implicated in age at menarche by G2G analysis of white European GWAS data (b) Time-resolved NDP- α MSH-stimulated cAMP
 906 production in HEK293 cells expressing *MC3R*-alone or with both *MC3R* and *GPR83*. Data are mean (standard error) % of the maximal
 907 *MC3R*-alone response (from 6 independent experiments). (c) Predicted mean (95% CI) age at menarche according to dosage of
 908 *MC3R* function-increasing C alleles at rs3746619 (X-axis in each panel) and *GPR83* expression-increasing T alleles at rs592068
 909 (panels). $\beta_{\text{interaction}} = -0.034 \pm 0.015$ years, $P_{\text{interaction}} = 0.02$. Extended data are included in Supplementary Tables 28 and 30.

910 **Methods**

911 **GWAS meta-analysis for age at menarche**

912 Association summary statistics were collated from studies on age at menarche (AAM,
913 predominantly recalled in adulthood) and genome-wide SNP arrays imputed to the
914 1000 Genomes reference panel or more recent (Supplementary Table 1). Genetic
915 variants and individuals were filtered based on study-specific quality control metrics.
916 In each study, genetic variants were tested for association with AAM in additive linear
917 regression models, including as covariates: age and any study-specific variables, such
918 as genetic principal components. Insertion and deletion polymorphisms were coded
919 as “I” and “D” to allow harmonization across all studies. Association statistics for each
920 SNP were then processed centrally using a standardized quality control pipeline⁶⁹.
921 Each variant was meta-analysed using a fixed-effects inverse-variance-weighted
922 model using METAL⁷⁰. This was done in two stages. First, summary statistics from
923 studies within each stratum (i. ReproGen consortium studies, ii. reproductive cancer
924 consortium studies, iii. East Asian studies) were meta-analysed and then filtered to
925 include only variants present in more than half of the studies within each stratum.
926 Second, strata-level results were meta-analysed with data from UK Biobank⁷¹, using
927 ‘first instance’ data for AAM (field 2714), and 23andMe. Initially we performed a
928 European-only analysis (N=632,955). This combined file was filtered to include only
929 variants present in the UK Biobank and at least one other stratum. Variants were also
930 filtered to include minor allele frequency (MAF) $\geq 0.1\%$. We then performed a second
931 analysis, by adding the data from the East-Asian studies, and followed the same
932 sample filtering steps and identification of independent signals (described below).

933 **Replication and explained variance**

934 Independent replication of identified signals was performed in data from the Danish
935 Blood Donors study¹⁶ (DBDS). The DBDS includes questionnaire recalled AAM data
936 on 35,472 European women (“Age when menstruation started?”). Mean age at recall
937 was 38.4 years (SD=12.9 years) and mean AAM was 13.1 years (SD=1.4 years).
938 Indirect confirmation of AAM signals was sought by association with age at voice
939 breaking (AVB) in men in UK Biobank¹⁷ (N=191,235 European men - data field 2385)
940 and the 23andMe study¹⁸ (N=55,781 European men). For signals with missing data
941 for either AVB dataset, we identified proxies using the UK Biobank White European
942 dataset (within 1Mb of the reported signal and $R^2 > 0.6$), choosing the variant with the
943 highest R^2 value. Given the smaller sample sizes of these cohorts, we performed a
944 Binomial sign test for global replication. The variance explained by each lead AAM
945 signal in the DBDS was calculated using the formula $2 \times f(1-f)\beta_a^2$, where f denotes the
946 variant MAF and β_a is the effect estimate in additive models. Overall variance
947 explained was calculated as the sum of individual variants.

948 **UK Biobank phenotype preparation**

949 For downstream analyses in UK Biobank, we derived a AAM variable, using data from
950 field 2714. To maximise sample size, individuals with missing or implausibly early or
951 late 'first instance' AAM (<8 years or >19 years old) were imputed using data from the
952 next available instance (if plausible). We also derived two binary traits to represent
953 abnormally early (precocious) and delayed puberty. Early puberty was defined as AAM
954 <10 years old (N=1,321). Delayed puberty was defined as AAM >15 years old
955 (N=10,530). For comparison, women reporting AAM at 12 or 13 years were controls
956 (N=81,950). All data analysis and visualisation were conducted in R (version 4.2.1,
957 2022-06-23), unless otherwise stated.

958 **Rare variant associations with age at menarche**

959 To identify gene-level rare variant associations with AAM, we performed an exome-
960 wide association study analysis (ExWAS) using whole-exome sequencing (WES) data
961 on 222,283 UK Biobank women of European genetic-ancestry⁷². WES data
962 processing and quality control was performed as described by Gardner *et al.*³⁰.
963 Individual gene burden tests were performed by collapsing variants with MAF <0.1%
964 per gene according to their predicted functional consequence. We defined two
965 functional categories of rare variants i) high confidence protein truncating variants (HC
966 PTV) annotated using VEP⁷³ and LOFTEE⁷⁴ and ii) damaging variants (DMG)
967 including HC PTVs plus missense variants with CADD score¹⁹ ≥ 25 . We analysed a
968 maximum of 17,885 protein-coding genes, each with at least 10 rare allele carriers in
969 either of the two variant categories ($P < 1.54 \times 10^{-6}$, 0.05/32,434 tests). Gene burden
970 association tests were performed using BOLT-LMM⁷⁵. Validity of the ExWAS analysis
971 was indicated by the absence of significant association with the synonymous variant
972 mask (Supplementary Figure 1) and low exome-wide inflation scores (λ -PTV = 1.047
973 and λ -DMG = 1.047). Where applicable, protein domains were annotated using
974 information from UniProt⁷⁶ and domain-level burden tests were then performed using
975 linear models.

976 **Rare variant associations with other traits**

977 We assessed the associations of any ExWAS AAM-associated genes in UK Biobank
978 with a range of related phenotypes: age at natural menopause (based on field 3581),
979 body mass index (BMI, field 21001), comparative body size age 10 (field 1687), adult
980 height (field 50), comparative height age 10 (field 1697), and circulating IGF-1
981 concentrations (field 30770). We considered only the top AAM-associated variant
982 mask for each gene. We also performed a similar look-up of these genes across a
983 broader range of phenotypes using the AstraZeneca Portal⁷⁷.

984 **Rare variants in IHH panel app genes**

985 We selected high evidence (“green”) genes with an established monoallelic/X-linked
986 mode of inheritance from the routine clinical investigation Genomics England gene
987 panel for idiopathic hypogonadotropic hypogonadism (IHH). At the time of the study,
988 this included four genes, *ANOS1*, *CHD7*, *FGF8* and *WDR11*. We performed a look-up
989 of these genes in the UK Biobank WES data for AAM (N=222,283) and VB
990 (N=178,625) considering only HC PTVs with MAF <0.1%. We also extracted the
991 phenotype of individual carriers. As in the ExWAS analysis, normal pubertal timing
992 was defined in women as AAM between 10-15 years of age¹ and in men as AVB at an
993 “about average age” (UK Biobank data field 2385).

994 **Polygenic score calculation**

995 We calculated a genome-wide polygenic score (PGS) for AAM using lassosum³¹. To
996 keep PGS generation independent of PGS testing, we generated the PGS using our
997 European-ancestry GWAS data excluding UK Biobank. We randomly selected 25,000
998 unrelated Europeans in UK Biobank to generate the LD (Linkage Disequilibrium)
999 reference. The resulting PGS was standardised, by subtracting the mean and dividing
1000 by the standard deviation.

1001 We divided the PGS into 100 centiles, and calculated the mean AAM for each PGS
1002 centile, as well as PGS centile-specific odds ratios for precocious or delayed AAM (as
1003 defined above) compared to individuals in the 50th centile of the PGS. We also
1004 calculated the mean PGS for each completed whole year of AAM.

1005 We next tested whether carriage of ExWAS AAM-associated rare variants modifies
1006 the influence of the PGS on AAM. We performed linear models that included
1007 interaction terms [PGS × rare variant carrier status] in the subsample of unrelated
1008 white-European UK Biobank women with WES, PGS and AAM data (N=187,941). To
1009 test for chance effects due to low sample size, we randomly subsampled non-carriers
1010 to a sample size equivalent to that of carriers and compared this distribution of AAM
1011 to that observed in carriers.

1012 A PGS comprising the 882 available lead AAM SNPs or their proxies (out of the 935
1013 independent AAM signals from the EUR-MA) was computed in 3,140 girls with
1014 available imputed GWAS data from the ALSPAC study. Linear or logistic regression
1015 models for continuous AAM, early AAM (-2 SDs, corresponding to <10.38 years), and
1016 delayed AAM (+2 SDs, corresponding to >14.95 years) were tested, controlling for the
1017 first 20 genetic PCs. Other models assessed the predictive performance of BMI at age
1018 8 years, and mother’s AAM; finally a model including all predictors as covariables was
1019 calculated. The predictive performance of each model was evaluated by the R^2 metric
1020 for continuous AAM and by the area under the receiver operating characteristic curve
1021 (AUROC) for binary AAM outcomes.

1022 **GWAS to Genes (G2G) pipeline**

1023 ***Mapping GWAS signals to genes***

1024 To perform signal selection, GWAS AAM summary statistics were filtered to remove
1025 variants with MAF <0.1%. The remaining variants were merged with allele information
1026 from UK Biobank to provide the genomic sequence for any missing alleles. Genome-
1027 wide significant signals ($P < 5 \times 10^{-8}$) were selected initially based on proximity (in 1Mb
1028 windows). Secondary signals within these windows were then identified using
1029 approximate conditional analysis (GCTA⁷⁸), using an LD reference panel derived from
1030 25,000 randomly selected UK Biobank participants. Secondary signals were defined
1031 as uncorrelated ($R^2 < 0.05$) with another signal and without an overt change in their
1032 AAM association between baseline and conditional models (change in beta <20% or
1033 change in P -value by less than four orders of magnitude). Primary and secondary AAM
1034 signals were further checked for pairwise LD within 10 Mb windows using plink
1035 (v1.90b6.18)⁷⁹ and only independent signals ($R^2 < 0.05$) were retained, prioritising
1036 distance-based signals in the case of linkage. Signal selection was performed first
1037 using the European-ancestry GWAS meta-analysis, and then supplemented by any
1038 signals identified by the All-ancestry GWAS meta-analysis that were uncorrelated
1039 ($R^2 < 0.05$) with any European-ancestry signal.

1040 Independent GWAS AAM signals were examined for proximal genes, defined as those
1041 within 500kb up- or downstream of the genes start or end sites, using the NCBI RefSeq
1042 gene map for GRCh37 (via
1043 <http://hgdownload.soe.ucsc.edu/goldenPath/hg19/database/>).

1044 ***Colocalization with expression or protein QTL data***

1045 Tissue enrichment for GWAS associations was performed using LD score regression
1046 applied to tissue-specific expression (LDSC-SEG)⁸⁰ and tissue-specific annotations
1047 from GTEx, accessed via <https://github.com/bulik/ldsc/wiki/Cell-type-specific-analyses>.
1048 Significantly enriched tissues ($P < 0.05$) were then included in colocalization
1049 analyses with the tissue-specific and cross-tissue meta-analysed GTEx eQTL data
1050 (V7⁶⁰, available via <https://gtexportal.org> and using the fixed-effects summary statistics
1051 for the latter), in addition to data from the eQTLGen⁸¹ and Brain-eMeta⁵⁹ studies.

1052 Including genomic variants with at least suggestive association with AAM (GWAS
1053 $P < 5 \times 10^{-5}$), we applied Summary data-based Mendelian Randomization and
1054 Heterogeneity in Independent Instruments (SMR-HEIDI, version 0.68⁸²) and the
1055 Approximate Bayes Factor (ABF) method in the R package “coloc” (version 5.1.0⁸³).
1056 For the former, we considered gene expression to be influenced by the same GWAS
1057 AAM variant if the FDR-corrected SMR test $P < 0.05$ and HEIDI test $P > 0.001$. For the
1058 latter, genomic regions were defined as ± 500 kb around each gene and loci exhibiting
1059 a H4 posterior probability > 0.75 were considered to show evidence of colocalization.

1060 We also tested for colocalization between GWAS AAM variants and pQTLs using data
1061 from the Fenland study⁸⁴ and using the same procedure as above. It is important to
1062 note that colocalization analysis cannot determine causal relationships or the direction
1063 of causality between the two phenotypes.

1064 ***Mapping GWAS signals to enhancers and coding variants***

1065 For genes proximal to (within 500 kb) GWAS AAM signals, we calculated genomic
1066 windows of high LD ($R^2 > 0.80$) around each signal and mapped these to the locations
1067 of known enhancers for the genes, using activity-by-contact (ABC) enhancer maps³⁴.
1068 This was done across the 131 available cell/tissue types and genes were matched to
1069 enhancers only in the tissues/cells where they were actively expressed.

1070 We also checked whether GWAS AAM signals were in LD ($R^2 > 0.80$) with any coding
1071 variants within the paired genes and what the predicted consequence of those coding
1072 variants, using SIFT⁸⁵ and POLYPHEN⁸⁶.

1073 ***Gene-level GWAS associations with AAM***

1074 We performed a gene-level MAGMA analysis³⁵, which collapses common GWAS
1075 variants within each gene and calculates aggregate gene-level associations with the
1076 outcome trait, as described by de Leeuw et al.³⁵. To enhance validity of this approach,
1077 we restricted the analysis to include only coding variants. Genes with FDR-corrected
1078 MAGMA $P < 0.05$ were considered associated with AAM.

1079 Finally, we used the Polygenic Priority Score (PoPS³⁶), which is a similarity-based
1080 gene prioritisation method and uses cell-type specific gene expression, biological
1081 pathways, and protein-protein interactions to prioritise likely causal genes from GWAS
1082 data. At each locus, the gene with the numerically highest PoPS score was determine
1083 to be the PoPS-prioritised gene.

1084 ***Calculation of G2G scores***

1085 From the above analyses, gene-level results were scored for each of the six sources
1086 as follows:

- 1087 1. **Closest gene.** Gene proximity to a GWAS signal is a good predictor of causality³⁷.
1088 The genes closest to each AAM signal (if also within 500 kb) were assigned. All
1089 genes with an intragenic signal were assigned as closest. Closest genes were
1090 scored 1.5 points.
- 1091 2. **eQTL colocalisation.** Genes with evidence of eQTL colocalisation via both SMR-
1092 HEIDI and coloc were scored 1.5 points. Genes with evidence of colocalisation via
1093 only one of these received 1.0 point. A further (1.0) point was assigned to genes if

1094 the most likely shared causal variant between eQTL and GWAS AAM was
1095 independent of the proximal GWAS signal ($R^2 < 0.05$).

- 1096 3. **pQTL colocalisation.** The same scoring as in (2) was applied to pQTL analyses.
- 1097 4. **Coding variants.** As the evidence was overlapping for coding variant gene-level
1098 MAGMA analysis and signals correlated with coding variants, these analyses were
1099 scored concomitantly. Genes with an FDR-corrected MAGMA $P < 0.05$ were scored
1100 0.5 points. Genes containing coding variants of deleterious or damaging predicted
1101 consequence in LD with GWAS AAM signals were scored 1.0 point, or only 0.5
1102 points if the coding variants were predicted to be benign or tolerated.
- 1103 5. **ABC enhancers.** Genes targeted by enhancers which overlapped with or were
1104 correlated with GWAS AAM signals were scored 1.0 point.
- 1105 6. **PoPS.** PoPs prioritised genes at each locus were scored 1.5 points.

1106 G2G scores for each gene-signal pair were calculated as the sum of scores from these
1107 six sources. Genes that scored > 0 points and were located within 500 kb of a GWAS
1108 AAM signal were considered further. To account for confounding due to large LD
1109 blocks, G2G scores were adjusted for signal LD window size (defined as the genomic
1110 distance containing variants with pairwise $R^2 > 0.50$ with the lead SNP) using linear
1111 regression models.

1112 For genes proximal to more than one GWAS AAM signal (and hence with multiple
1113 G2G scores), the signal with the most concordant sources for that gene (highest
1114 residual G2G score) was retained and a further (1.0) point was added to reflect
1115 evidence from multiple signals. This resulted in a unique summarised G2G score for
1116 each included gene. To account for confounding due to gene size, G2G scores were
1117 further adjusted for gene length using linear regression models. The resulting residuals
1118 were considered to be the final G2G scores.

1119 To prioritise likely causal AAM genes, all G2G scored genes (i.e., highlighted as
1120 potentially causal by at least one source) were ranked and also allocated a G2G centile
1121 position. In addition, the number of concordant predictors (sources) for each gene
1122 were noted (range: 1 to 6 sources). Finally, to reflect uncertainty due to multiple high
1123 scoring genes for the same signal, genes were flagged if they were proximal (within 1
1124 Mb) to other genes with a similar G2G score (within 0.5 points or greater, and
1125 highlighted by at least the same number of sources).

1126 ***High-confidence AAM genes***

1127 Independent GWAS signals from the All- and the European-ancestry meta-analyses
1128 were annotated with their top G2G scoring gene, using corresponding GWAS data
1129 (i.e., European analysis signals were annotated with genes from the European G2G,
1130 etc.). Genes implicated by at least two concordant sources were considered to be
1131 high-confidence AAM genes.

1132 High-confidence AAM genes were functionally annotated using STRING⁸⁷. Links to
1133 rare monogenic disorders were annotated from the Online Mendelian Inheritance in
1134 Man (OMIM) database (via Online Mendelian Inheritance in Man, OMIM®. McKusick-
1135 Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD),
1136 accessed November 2022. World Wide Web URL: <https://omim.org/>). Finally, we used
1137 GTEx, a publicly available resource of tissue-specific gene expression, to lookup the
1138 tissue expression of 1080 AAM genes highlighted by G2G⁶⁰.

1139 **ZNF483 genome-wide binding analysis**

1140 We used fGWAS (v.0.3.6³²), a hierarchical model for joint analysis of GWAS and
1141 genomic annotations, to test for enrichment of GWAS AAM signals among ZNF483
1142 transcription factor binding sites. fGWAS models a maximum likelihood parameter
1143 estimate for enrichment of a transcription factor (in this case ZNF483). To perform this,
1144 we annotated the European-ancestry GWAS AAM summary statistics with the ZNF483
1145 binding sites from the ENCODE ChIP-seq data derived from human HepG2 cell line
1146 (ENCSR436PIH).

1147 We also used Signed LD Profile regression (SLDP, <https://github.com/yakirr/sldp>,
1148 Reshef *et al.*³³) to explore the directional effect of ZNF483 function on AAM. We tested
1149 whether alleles that are predicted to increase the binding of ZNF483 have a combined
1150 tendency to increase or decrease AAM. SLDP requires signed LD profiles for ZNF483
1151 binding, a signed background model and reference panel in a SLDP compatible
1152 format. We used a 1000 Genomes Phase 3 European reference panel containing
1153 approximately 10M SNPs and 500 individuals.

1154 **Clustering of AAM signals by early childhood body weight**

1155 We analysed repeated measurements of early childhood body weight from the MoBa
1156 cohort study^{52,88} to investigate the relationship between early growth and puberty
1157 timing. Childhood body weight values were extracted from the study questionnaires
1158 for 12 different time-points from birth to age 8 years using previously reported
1159 exclusion criteria⁵². Weight values were standardized and adjusted for sex and
1160 gestational age using the generalized additive model for location, scale and shape
1161 (GAMLSS; v5.1-7, via www.gamlss.com) in R (v3.6.1) as previously reported⁵² with
1162 the exception that a Box-Cox t distribution was used to standardize body weight values
1163 (instead of the log-normal distribution used for BMI)⁵². GWAS for these traits was
1164 performed using BOLT-LMM (v2.3.4) as previously reported⁵².

1165 We performed Mendelian randomisation (MR) analyses to assess the likely causal
1166 effects of AAM on childhood weight at each time-point⁸⁹. As instrumental variables
1167 (IVs), we used all 1080 AAM-associated lead SNPs individually. As outcome data, we
1168 used childhood weight at the 12 time-points. For SNPs with missing outcome data, we

1169 identified proxies within 1 Mb and $R^2 > 0.6$, choosing the variant with the highest R^2
1170 value, using a random selection of 25,000 unrelated European-ancestry UK Biobank
1171 individuals for the LD reference. Genotypes at all variants were aligned to the AAM-
1172 increasing allele. We used inverse-variance weighted (IVW) MR models, as this has
1173 the greatest statistical power⁹⁰.

1174 Next, we stratified the 1080 AAM lead SNPs by their effects on early childhood weight
1175 used a k-means clustering approach for longitudinal data⁹¹. We performed five
1176 different models with k-means for $k \in \{2, 3, 4, 5, 6\}$ clusters 20 times each. To find the
1177 optimal partition, we used the “nearlyAll” option which uses several different
1178 initialisation methods in alternation. As the assumption of homoscedasticity was not
1179 met, we used the Carolinski-Harabatz criterion, a non-parametric quality criterion, to
1180 derive the optimal number of clusters.

1181 We then performed additional MR analyses, combining AAM signals within each
1182 identified cluster as IVs and, as the outcomes, childhood weight at each time-point
1183 and also adult BMI (on $N = 450,706$ UK Biobank participants). We grouped together
1184 ‘high early weight’ and ‘moderate early weight’ AAM SNPs into a single IV to maximise
1185 power.

1186 **Biological pathway enrichment analysis**

1187 We performed gene-centric biological pathway enrichment analysis using g:Profiler
1188 (via the R client “gprofiler2”, version 0.2.1⁵³). We used a filtered set of GO pathways
1189 (accessed on the 21/02/2023), focusing on GO:BP, KEGG and REACTOME, and
1190 restricted the analysis to those pathways with 1000 genes or fewer, reasoning that
1191 these are more biologically specific. Pathway enrichment analyses were performed
1192 using the set of 660 high-confidence AAM genes, and repeated when stratified by their
1193 effects on early childhood weight (see above). Pathways with Bonferroni corrected
1194 $P < 0.05$ were considered to be associated with AAM.

1195 As the pathways derived from overlapping sources, we clustered the AAM-associated
1196 pathways to aid interpretation. Clustering was based on shared AAM genes across
1197 pathways. We used a “complete” clustering algorithm and a custom distance
1198 calculated as [one minus the proportion of the overlap between any two pathways
1199 relative to the pathway with the smaller overlap]. Thus, between two pathways a value
1200 of 0 indicates that all the shared AAM genes in the pathway with fewer genes are also
1201 enriched in the other pathway. To define clusters, we chose an arbitrary overlap value
1202 of 0.5, which indicates that pathways in the same cluster share 50% or more of their
1203 AAM genes.

1204 Each pathway cluster was annotated by i) the pathway with the most significant
1205 enrichment, ii) the pathway with the highest proportion of AAM genes, iii) biological
1206 coherence of the pathways, and iv) shared genes common to all included pathways.

1207 We considered that pathways were overlapping between the total AAM gene set and
1208 the two early-weight subgroups if there were common pathways across either i) the
1209 most significant pathway or ii) the pathway with the highest proportion of AAM-
1210 associated genes.

1211 **Expression of AAM genes in GnRH neurons**

1212 We tested for enrichment of AAM-associated genes in RNAseq data from embryonic
1213 GnRH mouse neurons [manuscript in preparation]. All expressed genes were sorted
1214 into different expressional trajectories, based on shared dynamic expression profiles
1215 across three developmental stages (early, intermediate or late), as described by
1216 Pitteloud et al. [manuscript in preparation]. We tested for enrichment of AAM-
1217 associated genes (from our European-ancestry GWAS meta-analysis) in any identified
1218 trajectory, using MAGMA³⁵ with custom pathways. As a sensitivity test, we used
1219 Fisher's Exact test to confirm over-representation of AAM-associated genes within
1220 each trajectory.

1221 **Colocalization of AAM signals with BMI and menopause**

1222 To explore the shared genetic architecture between AAM, age at natural menopause
1223 (ANM) and adult BMI, we performed a colocalization analysis for each of the 1080
1224 AAM signals. ANM GWAS summary statistics were from reported ReproGen data on
1225 ~250,000 women of European ancestry⁶². Adult BMI GWAS summary statistics were
1226 derived from 450,706 individuals in UK Biobank. For AAM signals with missing
1227 outcome GWAS data, we identified proxies within 1 Mb and with an $R^2 > 0.6$ using our
1228 25,000 participant UK Biobank LD reference. We applied both Bonferroni correction
1229 ($P \leq 0.05/1080 = 4.6 \times 10^{-5}$) for association with the outcome trait, and a posterior
1230 probability (PP) of colocalization $PP > 0.5$.

1231 The same approach was applied in the opposite direction, by testing ANM signals
1232 identified in the most recent ReproGen GWAS⁶² for association with AAM. ANM
1233 signals were highlighted if they passed Bonferroni correction ($P \leq 0.05/290 = 1.7 \times 10^{-4}$)
1234 for association with AAM. As ANM signals are well-established to be enriched for DNA
1235 damage repair genes (DDR), we built a comprehensive list of DDR genes, integrating
1236 five different sources: i) an expert curated DDR gene list ("Broad DDR") from the
1237 laboratory of Professor Stephen Jackson, this list encompasses a range of related
1238 pathways: DNA repair genes, broader DNA damage response genes (such as
1239 damage-induced chromatin remodelling, transcription regulation or cell cycle
1240 checkpoint induction); and general maintenance of genome stability (such as genes
1241 involved in DNA replication); ii) a second expert curated list previously reported⁶²,
1242 assembled by John Perry, Eva Hoffmann and Anna Murray; iii) genes listed in the
1243 REACTOME⁹² "DNA Repair" pathway (R-HSA-73894); iv) genes listed in the Gene

1244 Ontology “DNA Repair” pathway (GO:0006281); and v) genes listed in the Gene
1245 Ontology⁹³ “Cellular response to DNA damage stimulus” (GO:0006974).

1246 **GPR83-MC3R interaction**

1247 ***Brain expressed GPCRs***

1248 We tested whether any brain-expressed G-protein coupled receptors (GPCRs) were
1249 implicated by GWAS AAM associations (G2G gene scores). We tested a curated list
1250 of brain-expressed GPCRs (Stephen O’Rahilly, personal communication): ACKR1,
1251 ACKR2, ACKR3, ACKR4, ADRB1, ADRB2, ADRB3, AGTR1, AGTR2, BRS3, C5AR1,
1252 C5AR2, CALCR, CASR, CCKAR, CCR1, CCR10, CCR2, CCR3, CCR4, CCR5,
1253 CCR6, CCR7, CCR9, CCRL2, CNR1, CNR2, CXCR1, CXCR2, CXCR3, CXCR4,
1254 CXCR6, DRD1, DRD2, DRD3, DRD4, DRD5, EDNRA, EDNRB, FFAR1, FFAR2,
1255 FFAR3, FFAR4, FPR1, FPR2, FPR3, FSHR, GALR1, GALR2, GALR3, GHRHR,
1256 GHSR, GIPR, GLP1R, GLP2R, GNRHR, GPER1, GPR1, GPR12, GPR15, GPR17,
1257 GPR18, GPR19, GPR20, GPR22, GPR25, GPR26, GPR27, GPR3, GPR34, GPR35,
1258 GPR37, GPR39, GPR4, GPR42, GPR45, GPR52, GPR55, GPR6, GPR61, GPR62,
1259 GPR63, GPR75, GPR78, GPR82, GPR83, GPR84, GPR85, GPR87, GPR88, GRM1,
1260 GRM2, GRM3, GRM4, GRM5, GRM6, GRM7, GRM8, GRPR, HCAR1, HCAR2,
1261 HCAR3, HRH1, HRH2, HRH3, HRH4, LGR4, LGR5, LGR6, LPAR1, LPAR2, LPAR3,
1262 LPAR4, LPAR5, LPAR6, MC3R, MC4R, MC5R, MCHR1, MCHR2, NMBR, NMUR1,
1263 NMUR2, NPSR1, NPY1R, NPY2R, NPY4R, NPY5R, NPY6R, OXER1, OXGR1,
1264 P2RY1, P2RY2, P2RY4, P2RY6, P2RY8, PRLHR, PTAFR, PTH1R, PTH2R, QRFPR,
1265 RGR, RXFP1, RXFP2, S1PR1, S1PR2, S1PR3, S1PR4, S1PR5, SCTR, SSR1, SSR2,
1266 SSR3, SSR4, TSHR, VIPR1, VIPR2, VN1R1, VN1R2, VN1R5 and XCR1. For any
1267 GPCR scored by our G2G AAM pipeline, colocalisation was tested between GWAS
1268 signals for AAM and adult BMI (colocalisation methods as described above).

1269 ***Cell culture and transfection***

1270 To investigate the effect of *GPR83* of MC3R signalling, we performed *in vitro* assays
1271 in transiently transfected HEK293 cells maintained in Dulbecco’s modified eagle
1272 medium (high glucose DMEM, GIBCO, 41965) supplemented with 10% fetal bovine
1273 serum (GIBCO, 10270), 1% GlutaMAX™ (100X) (GIBCO, 35050), and 100 units/mL
1274 penicillin and 100 mg/mL streptomycin (Sigma-Aldrich, P0781). Cells were incubated
1275 at 37°C in humidified air containing 5% CO₂ and transfections were performed using
1276 Lipofectamine 2000 (GIBCO, 11668) in serum-free Opti-MEM I medium (GIBCO,
1277 31985), according to the manufacturer’s protocols. The plasmids used encode the C-
1278 FLAG-tagged human *GPR83* WT (NM_016540.4) or N-FLAG-tagged human MC3R
1279 WT (NM_019888.3) ligated into pcDNA3.1(+) (Invitrogen).

1280 ***Bioluminescence Resonance Energy Transfer (BRET) to measure dimerization***

1281 Heterodimerization between *GPR83* and *MC3R* was quantified using BRET1 in
1282 titration configuration. Briefly, 12,000 HEK293 cells seeded in 96-well plates were
1283 transfected with a constant dose of MC3R-RlucII plasmid (0.5 ng/well) and increasing
1284 doses of *GPR83*-Venus plasmids, or soluble (s) Venus as negative control. All
1285 conditions were topped up with empty vector (pcDNA3.1 (+)) to a total of 100 ng
1286 plasmid/well. Twenty-four hours post transfection, cells were washed once with
1287 Thyrode's buffer and total Venus fluorescence was measured in a Spark 10M
1288 Microplate reader (Tecan) using monochromators (excitation 485 ± 20 nm, emission
1289 535 ± 20 nm). BRET was quantified 10 minutes after the addition of coelenterazine H
1290 (NanoLight Technology, 2.5 mM). netBRET was calculated as $[(\text{absorbance at } 533 \pm 25 \text{ nm} / \text{absorbance at } 480 \pm 40 \text{ nm})] - [\text{background (absorbance at } 533 \pm 25 \text{ nm} / \text{absorbance at } 480 \pm 40 \text{ nm})]$, with the background corresponding to the signal in
1291 cells expressing the RlucII protomer alone under similar conditions. Data on the X-axis
1292 represent the ratio between acceptor (Venus) fluorescence and donor (RlucII)
1293 luminescence. Representative data are from four independent experiments.
1294
1295

1296 ***Time-resolved cAMP assay***

1297 Measurement of ligand-induced cAMP generation in HEK293 cells transiently
1298 expressing either *MC3R* or both *MC3R* and *GPR83* was performed using GloSensor™
1299 cAMP biosensor (Promega), according to manufacturer's protocol. Briefly, 12,000
1300 cells were seeded in white 96-well poly-D-lysine-coated plates. After 24 hours, cells
1301 were transfected with both 100 ng/well of pGloSensor™-20F cAMP plasmid
1302 (Promega, E1171) and 30 ng/well of each plasmid encoding either MC3R or MC3R
1303 and GPR83, using Lipofectamine 2000 (GIBCO, 11668). All conditions were topped
1304 up with empty vector (pcDNA3.1 (+)) to a total of 160 ng plasmid/well. The day after
1305 transfection, cell media were replaced by 90 mL of fresh DMEM with 2% v/v
1306 GloSensor™ cAMP Reagent (Promega, E1290) and incubated for 120 min at 37°C.
1307 Firefly luciferase activity was measured at 37°C and 5% CO₂ using a Spark 10M
1308 microplate reader (Tecan). After initial measurement of the baseline signal for 10 min
1309 (30 seconds intervals), cells were stimulated with 10 mL of 10x stock solution of the
1310 MC3R agonist NDP-aMSH (final concentration 1 mM) and real-time chemiluminescent
1311 signals were quantified for 25 minutes (30 seconds intervals). In each experiment, a
1312 negative control using mock transfected cells (empty pcDNA3.1(+) plasmid) was
1313 assayed. The area under the curve (AUC) was calculated for each cAMP production
1314 curve considering total peak area above the baseline calculated as the average signal
1315 for mock pcDNA3.1(+)-transfected cells. For data normalization, the AUC from mock
1316 transfected cells was set as 0 and the AUC from WT MC3R was set as 100%. Results
1317 are from six independent experiments.

1318 ***Genetic epistasis between GPR83 and MC3R***

1319 To corroborate the *in vitro* interaction, we tested for evidence of a specific epistatic
1320 interaction between AAM GWAS signals at *GPR83* (rs592068-C) and *MC3R*

1321 (rs3746619-A). We extracted genotypes for these SNPs in white-European unrelated
1322 UK Biobank women (N=204,303). After adjusting AAM for standard covariates (GWAS
1323 chip, age, sex, PC1-10), we modelled the interaction between genotype dosages at
1324 the two signals using a linear model.

1325

References

1. Parent, A.-S. *et al.* The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration. *Endocr. Rev.* **24**, 668–693 (2003).
2. Gajbhiye, R., Fung, J. N. & Montgomery, G. W. Complex genetics of female fertility. *NPJ Genomic Med.* **3**, 29 (2018).
3. McGrath, I. M., Mortlock, S. & Montgomery, G. W. Genetic Regulation of Physiological Reproductive Lifespan and Female Fertility. *Int. J. Mol. Sci.* **22**, 2556 (2021).
4. Elks, C. E. *et al.* Age at menarche and type 2 diabetes risk: the EPIC-InterAct study. *Diabetes Care* **36**, 3526–3534 (2013).
5. Prentice, P. & Viner, R. M. Pubertal timing and adult obesity and cardiometabolic risk in women and men: a systematic review and meta-analysis. *Int. J. Obes.* **2005** **37**, 1036–1043 (2013).
6. Bodicoat, D. H. *et al.* Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study. *Breast Cancer Res. BCR* **16**, R18 (2014).
7. Cheng, T. S., Ong, K. K. & Biro, F. M. Trends Toward Earlier Puberty Timing in Girls and Its Likely Mechanisms. *J. Pediatr. Adolesc. Gynecol.* **35**, 527–531 (2022).
8. Perry, J. R. B., Murray, A., Day, F. R. & Ong, K. K. Molecular insights into the aetiology of female reproductive ageing. *Nat. Rev. Endocrinol.* **11**, 725–734 (2015).
9. Day, F. R. *et al.* Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. *Nat. Genet.* **49**, 834–841 (2017).
10. Lunetta, K. L. *et al.* Rare coding variants and X-linked loci associated with age at menarche. *Nat. Commun.* **6**, 7756 (2015).
11. Elks, C. E. *et al.* Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. *Nat. Genet.* **42**, 1077–1085 (2010).
12. Perry, J. R. *et al.* Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. *Nature* **514**, 92–97 (2014).
13. Horikoshi, M. *et al.* Elucidating the genetic architecture of reproductive ageing in the Japanese population. *Nat. Commun.* **9**, 1977 (2018).
14. Hollis, B. *et al.* Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan. *Nat. Commun.* **11**, 1536 (2020).
15. Lam, B. Y. H. *et al.* MC3R links nutritional state to childhood growth and the timing of puberty. *Nature* **599**, 436–441 (2021).
16. Erikstrup, C. *et al.* Cohort Profile: The Danish Blood Donor Study. *Int. J. Epidemiol.* **dyac194** (2022) doi:10.1093/ije/dyac194.
17. Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med.* **12**, e1001779 (2015).
18. Day, F. R. *et al.* Shared genetic aetiology of puberty timing between sexes and with health-related outcomes. *Nat. Commun.* **6**, 8842 (2015).

19. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res.* **47**, D886–D894 (2019).
20. Young, J. *et al.* TAC3 and TACR3 defects cause hypothalamic congenital hypogonadotropic hypogonadism in humans. *J. Clin. Endocrinol. Metab.* **95**, 2287–2295 (2010).
21. Valadares, L. P. *et al.* MKRN3 Mutations in Central Precocious Puberty: A Systematic Review and Meta-Analysis. *J. Endocr. Soc.* **3**, 979–995 (2019).
22. Manotas, M. C., González, D. M., Céspedes, C., Forero, C. & Rojas Moreno, A. P. Genetic and Epigenetic Control of Puberty. *Sex. Dev. Genet. Mol. Biol. Evol. Endocrinol. Embryol. Pathol. Sex Determ. Differ.* **16**, 1–10 (2022).
23. Russwurm, C., Koesling, D. & Russwurm, M. Phosphodiesterase 10A Is Tethered to a Synaptic Signaling Complex in Striatum. *J. Biol. Chem.* **290**, 11936–11947 (2015).
24. Yasui, G. *et al.* Zinc finger protein 483 (ZNF483) regulates neuronal differentiation and methyl-CpG-binding protein 2 (MeCP2) intracellular localization. *Biochem. Biophys. Res. Commun.* **568**, 68–75 (2021).
25. Oleksiewicz, U. *et al.* TRIM28 and Interacting KRAB-ZNFs Control Self-Renewal of Human Pluripotent Stem Cells through Epigenetic Repression of Pro-differentiation Genes. *Stem Cell Rep.* **9**, 2065–2080 (2017).
26. Simon, D. *et al.* Mutations in the maternally imprinted gene MKRN3 are common in familial central precocious puberty. *Eur. J. Endocrinol.* **174**, 1–8 (2016).
27. Martin, A. R. *et al.* PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels. *Nat. Genet.* **51**, 1560–1565 (2019).
28. Shekari, S. *et al.* Monogenic causes of Premature Ovarian Insufficiency are rare and mostly recessive. 2022.11.21.22282589 Preprint at <https://doi.org/10.1101/2022.11.21.22282589> (2022).
29. Mirshahi, U. L. *et al.* Reduced penetrance of MODY-associated HNF1A/HNF4A variants but not GCK variants in clinically unselected cohorts. *Am. J. Hum. Genet.* **109**, 2018–2028 (2022).
30. Gardner, E. J. *et al.* Damaging missense variants in IGF1R implicate a role for IGF-1 resistance in the etiology of type 2 diabetes. *Cell Genomics* **2**, None (2022).
31. Mak, T. S. H., Porsch, R. M., Choi, S. W., Zhou, X. & Sham, P. C. Polygenic scores via penalized regression on summary statistics. *Genet. Epidemiol.* **41**, 469–480 (2017).
32. Pickrell, J. K. Joint analysis of functional genomic data and genome-wide association studies of 18 human traits. *Am. J. Hum. Genet.* **94**, 559–573 (2014).
33. Reshef, Y. A. *et al.* Detecting genome-wide directional effects of transcription factor binding on polygenic disease risk. *Nat. Genet.* **50**, 1483–1493 (2018).
34. Nasser, J. *et al.* Genome-wide enhancer maps link risk variants to disease genes. *Nat. 2021 5937858* **593**, 238–243 (2021).
35. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput. Biol.* **11**, e1004219 (2015).

36. Weeks, E. M. *et al.* Leveraging polygenic enrichments of gene features to predict genes underlying complex traits and diseases. 2020.09.08.20190561 Preprint at <https://doi.org/10.1101/2020.09.08.20190561> (2020).
37. Stacey, D. *et al.* ProGeM: a framework for the prioritization of candidate causal genes at molecular quantitative trait loci. *Nucleic Acids Res.* **47**, e3 (2019).
38. Aragam, K. G. *et al.* Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. *Nat. Genet.* **54**, 1803–1815 (2022).
39. Cangiano, B., Swee, D. S., Quinton, R. & Bonomi, M. Genetics of congenital hypogonadotropic hypogonadism: peculiarities and phenotype of an oligogenic disease. *Hum. Genet.* **140**, 77–111 (2021).
40. Sertedaki, A. *et al.* Whole Exome Sequencing Points towards a Multi-Gene Synergistic Action in the Pathogenesis of Congenital Combined Pituitary Hormone Deficiency. *Cells* **11**, 2088 (2022).
41. Butz, H., Nyíró, G., Kurucz, P. A., Likó, I. & Patócs, A. Molecular genetic diagnostics of hypogonadotropic hypogonadism: from panel design towards result interpretation in clinical practice. *Hum. Genet.* **140**, 113–134 (2021).
42. Herbison, A. E. Control of puberty onset and fertility by gonadotropin-releasing hormone neurons. *Nat. Rev. Endocrinol.* **12**, 452–466 (2016).
43. Parkin, K., Kapoor, R., Bhat, R. & Greenough, A. Genetic causes of hypopituitarism. *Arch. Med. Sci. AMS* **16**, 27–33 (2020).
44. Loos, R. J. F. & Yeo, G. S. H. The genetics of obesity: from discovery to biology. *Nat. Rev. Genet.* **23**, 120–133 (2022).
45. Zenker, M., Edouard, T., Blair, J. C. & Cappa, M. Noonan syndrome: improving recognition and diagnosis. *Arch. Dis. Child.* **107**, 1073–1078 (2022).
46. El Bouchikhi, I. *et al.* Noonan syndrome-causing genes: Molecular update and an assessment of the mutation rate. *Int. J. Pediatr. Adolesc. Med.* **3**, 133–142 (2016).
47. Forsythe, E. & Beales, P. L. Bardet-Biedl syndrome. *Eur. J. Hum. Genet. EJHG* **21**, 8–13 (2013).
48. Buiting, K., Williams, C. & Horsthemke, B. Angelman syndrome - insights into a rare neurogenetic disorder. *Nat. Rev. Neurol.* **12**, 584–593 (2016).
49. Cole, T. J., Ahmed, M. L., Preece, M. A., Hindmarsh, P. & Dunger, D. B. The relationship between Insulin-like Growth Factor 1, sex steroids and timing of the pubertal growth spurt. *Clin. Endocrinol. (Oxf.)* **82**, 862–869 (2015).
50. Mourouzis, I., Lavecchia, A. M. & Xinaris, C. Thyroid Hormone Signalling: From the Dawn of Life to the Bedside. *J. Mol. Evol.* **88**, 88–103 (2020).
51. Vazquez, M. J., Daza-Dueñas, S. & Tena-Sempere, M. Emerging Roles of Epigenetics in the Control of Reproductive Function: Focus on Central Neuroendocrine Mechanisms. *J. Endocr. Soc.* **5**, bvab152 (2021).
52. Helgeland, Ø. *et al.* Characterization of the genetic architecture of infant and early childhood body mass index. *Nat. Metab.* **4**, 344–358 (2022).
53. Kolberg, L., Raudvere, U., Kuzmin, I., Vilo, J. & Peterson, H. gprofiler2 -- an R package for gene list functional enrichment analysis and namespace conversion toolset g:Profiler. *F1000Research* **9**, ELIXIR-709 (2020).

54. Vassart, G. & Costagliola, S. G protein-coupled receptors: mutations and endocrine diseases. *Nat. Rev. Endocrinol.* **7**, 362–372 (2011).
55. Adams, F., Grassie, M., Shahid, M., Hill, D. R. & Henry, B. Acute oral dexamethasone administration reduces levels of orphan GPCR glucocorticoid-induced receptor (GIR) mRNA in rodent brain: potential role in HPA-axis function. *Brain Res. Mol. Brain Res.* **117**, 39–46 (2003).
56. Brézillon, S., Detheux, M., Parmentier, M., Hökfelt, T. & Hurd, Y. L. Distribution of an orphan G-protein coupled receptor (JP05) mRNA in the human brain. *Brain Res.* **921**, 21–30 (2001).
57. Müller, T. D. *et al.* The orphan receptor Gpr83 regulates systemic energy metabolism via ghrelin-dependent and ghrelin-independent mechanisms. *Nat. Commun.* **4**, 1968 (2013).
58. Lohse, M. J. Dimerization in GPCR mobility and signaling. *Curr. Opin. Pharmacol.* **10**, 53–58 (2010).
59. Qi, T. *et al.* Identifying gene targets for brain-related traits using transcriptomic and methylomic data from blood. *Nat. Commun.* **2018 91 9**, 1–12 (2018).
60. GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science* **348**, 648–660 (2015).
61. Day, F. R. *et al.* Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. *Nat. Genet.* **47**, 1294–1303 (2015).
62. Ruth, K. S. *et al.* Genetic insights into biological mechanisms governing human ovarian ageing. *Nature* **596**, 393–397 (2021).
63. Ruth, K. S. *et al.* Events in Early Life are Associated with Female Reproductive Ageing: A UK Biobank Study. *Sci. Rep.* **6**, 24710 (2016).
64. Mbarek, H. *et al.* Identification of Common Genetic Variants Influencing Spontaneous Dizygotic Twinning and Female Fertility. *Am. J. Hum. Genet.* **98**, 898–908 (2016).
65. Day, F. *et al.* Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. *PLoS Genet.* **14**, e1007813 (2018).
66. Thompson, D. J. *et al.* Genetic predisposition to mosaic Y chromosome loss in blood. *Nature* **575**, 652–657 (2019).
67. Lappalainen, T. & MacArthur, D. G. From variant to function in human disease genetics. *Science* **373**, 1464–1468 (2021).
68. Wen, S., Ai, W., Alim, Z. & Boehm, U. Embryonic gonadotropin-releasing hormone signaling is necessary for maturation of the male reproductive axis. *Proc. Natl. Acad. Sci. U. S. A.* **107**, 16372–16377 (2010).
69. Winkler, T. W. *et al.* Quality control and conduct of genome-wide association meta-analyses. *Nat. Protoc.* **9**, 1192–1212 (2014).
70. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinforma. Oxf. Engl.* **26**, 2190–2191 (2010).

71. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–209 (2018).
72. Backman, J. D. *et al.* Exome sequencing and analysis of 454,787 UK Biobank participants. *Nature* **599**, 628–634 (2021).
73. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, 122 (2016).
74. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* **581**, 434–443 (2020).
75. Loh, P.-R. *et al.* Efficient Bayesian mixed-model analysis increases association power in large cohorts. *Nat. Genet.* **47**, 284–290 (2015).
76. UniProt Consortium. UniProt: the Universal Protein Knowledgebase in 2023. *Nucleic Acids Res.* **51**, D523–D531 (2023).
77. Wang, Q. *et al.* Rare variant contribution to human disease in 281,104 UK Biobank exomes. *Nature* **597**, 527–532 (2021).
78. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. *Am. J. Hum. Genet.* **88**, 76–82 (2011).
79. Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).
80. Finucane, H. K. *et al.* Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. *Nat. Genet.* **50**, 621–629 (2018).
81. Võsa, U. *et al.* Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. *Nat. Genet.* **2021 539 53**, 1300–1310 (2021).
82. Zhu, Z. *et al.* Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nat. Genet.* **48**, 481 (2016).
83. Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS Genet* **10**, e1004383 (2014).
84. Pietzner, M. *et al.* Mapping the proteo-genomic convergence of human diseases. *Science* **374**, eabj1541 (2021).
85. Vaser, R., Adusumalli, S., Leng, S. N., Sikic, M. & Ng, P. C. SIFT missense predictions for genomes. *Nat. Protoc.* **2015 111 11**, 1–9 (2015).
86. Adzhubei, I., Jordan, D. M. & Sunyaev, S. R. Predicting Functional Effect of Human Missense Mutations Using PolyPhen-2. *Curr. Protoc. Hum. Genet.* **76**, 7.20.1-7.20.41 (2013).
87. Szklarczyk, D. *et al.* The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. *Nucleic Acids Res.* **49**, D605–D612 (2021).
88. Magnus, P. *et al.* Cohort profile: the Norwegian Mother and Child Cohort Study (MoBa). *Int. J. Epidemiol.* **35**, 1146–1150 (2006).
89. Smith, G. D. & Ebrahim, S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? *Int. J. Epidemiol.* **32**, 1–22 (2003).

90. Slob, E. A. W. & Burgess, S. A comparison of robust Mendelian randomization methods using summary data. *Genet. Epidemiol.* **44**, 313–329 (2020).
91. Genolini, C. & Falissard, B. Kml: a package to cluster longitudinal data. *Comput. Methods Programs Biomed.* **104**, e112-121 (2011).
92. Gillespie, M. *et al.* The reactome pathway knowledgebase 2022. *Nucleic Acids Res.* **50**, D687–D692 (2022).
93. Gene Ontology Consortium. The Gene Ontology resource: enriching a GOld mine. *Nucleic Acids Res.* **49**, D325–D334 (2021).